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The ISOLPHARM project has the aim of producing a set of innovative, high specific activity, carrier-
free radioisotopes for target radionuclide therapy exploiting the ISOL technique at the SPES facility
of INFN-LNL. The success of a particular radiopharmaceutical cancer treatment relies on an accurate
assessment of the tissue response and toxicity. Since biological effects are mediated by the absorbed
dose, which is defined as the energy absorbed per unit mass of tissue, internal dosimetry is of funda-
mental importance because it allows for the maximization of the therapeutic effect while minimizing
the radiation burden to other organs. This thesis work consists in the calculation of internal absorbed
dose, following radiopharmaceutical treatments — e.g. with 18F, 111In or 111Ag — by means of different
Monte Carlo based approaches (using the Geant4 software) coupled with PET/CT and SPECT/CT





Il progetto ISOLPHARM nasce con lo scopo di produrre una serie di radioisotopi innovativi per
l’utilizzo in terapia radiofarmaceutica sfruttando la tecnica ISOL nella facility SPES di INFN-LNL.
Il successo di un trattamento radiofarmaceutico su un tumore dipende da un’accurata valutazione
della risposta del tessuto e della tossicità. Poiché gli effetti biologici sono mediati dalla dose assorbita,
definita come energia assorbita per unità di massa del tessuto, la dosimetria interna è d’importanza
fondamentale per permettere la massimizzazione dell’effetto terapeutico minimizzando l’irraggiamento
degli altri organi. Il lavoro di tesi consiste nel calcolo della dose assorbita internamente a seguito di
trattamenti radiofarmaceutici — per esempio con 18F, 111In o 111Ag — avvalendosi di diversi approcci
basati sul metodo Monte Carlo (utilizzando il software Geant4) abbinato a immagini PET/CT o





The initial part of this thesis is meant to provide the reader with some background information
needed to understand properly the requirements, the choices and the strategies that will characterize
the following research. In order to accomplish this purpose, the first chapter will be dedicated to a
general recap of medical physics methods: after a preliminary exposition of the main radiobiological
quantities at stake, an introduction to Target Radionuclide Therapy (TRT) will be given; then, an
excursus will be held about the medical imaging techniques which will be used later in this work, i.e.:
 Computed Tomography (CT);
 Single Photon Emission Computed Tomography (SPECT);
 Positron Emission Tomography (PET).
Achieved this, Chapter 2 will introduce to the reader the story, the main goals, the research methods
and the technologies involved in the INFN-ISOLPHARM project [1]. The Isotope Separation On-Line
(ISOL) technique for the creation of Radioactive Ion Beams (RIBs) will be presented in detail as
a fundamental feature of the entire experiment; that will be followed by an explanation of how the
ISOL technique can be matched to the production of highly pure carrier-free radionuclides thanks to
chemical processes and, later, of the final radiopharmaceuticals to be used in nuclear medicine for
therapy, diagnosis or — as it will be shown — both at the same time.
Subsequently, the reader will be ready to face the research activities carried out in the context of
this master thesis. These studies deal with dosimetric predictions of the effectiveness of innovative
radiopharmaceuticals in biological tissues, in particular those of a sample of mice; the reasons why
such calculation is so important to ISOLPHARM will be widely discussed in Chapter 2. The different
methods used are two, and they both have recourse to medical imaging and to Monte Carlo simula-
tions from the Geant4 software [2].
The first strategy, exposed in Chapter 3, consists in generating virtual volumes of several tissues subdi-
vided in concentric shells or in voxels (namely 3D pixels), simulating either monoenergetic electrons or
radioisotopic sources not dependent on time and building a database of mean absorbed dose per event
values. These coefficients, called Dose Point Kernels (DPKs) in the shell case and Voxel S-Values
(VSVs) in the voxel one, form a kernel that can be convolved with a function expressing the activity
— e.g. taken from a PET or a SPECT — in order to estimate the dose absorbed by the tissues from a
real source. Certain radionuclides already used in medical physics will be studied and compared with
the existing literature and then the innovative species of ISOLPHARM such as 111Ag will be analyzed.
Regarding the second method, which will be treated in Chapter 4, PET/CT and SPECT/CT coupled
images will be exploited to reproduce virtual voxel-made murine bodies (using CT) as sensitive vol-
umes of Geant4 and to get information about the time evolution of the activity biodistribution (PET,
SPECT). In this way, the radiation dose could be directly simulated for any radionuclide inserted
in a radiopharmaceutical whose biodistribution is equivalent to the ones used during the imaging
processes. The final aim is to build a tool able to predict and study the dose maps that will char-










Some concepts of medical physics
It is worthwhile to begin this master thesis with a short recap of certain features of medical physics
that will be helpful for a complete comprehension of the following topics. First of all, some general
notions about the physical quantities used in dosimetry and radiobiology will be provided; then some
modern techniques of radiation therapy will be introduced, with particular attention paid to Tar-
get Radionuclide Therapy (TRT) because of its primary relevance in the ISOLPHARM experiment.
Finally, as disclosed in the Introduction, the imaging techniques which may be useful for predictive
dosimetry calculation will be presented in detail: we are talking about Computed Tomography (CT),
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT).
1.1 Main quantities
Since we are going to deal with medical applications of radioactivity, the first physical quantity to
introduce is naturally the activity of a source, i.e. its radioactive decays per time unit; it can be
thought as the opposite time derivative of the number of nuclides of a decaying population: calling









and clearly having the dimensions of an inverse time; an alternative unit is the curie, defined as
1 Ci = 37 GBq. Since N(t) in such systems shows a negative exponential trend
N(t) = N0 e
−λt (1.3)
where N0 is the initial number of nuclides of that species and λ is the radioactive disintegration constant
(or simply decay constant), the following equation holds




−λt) = λN0 e−λt = λN(t) (1.4)
meaning that, if A(t) is measured from a source of a known species, we also know the number of nuclei
N(t), being λ a constant. The latter can be related as well to observable quantities, since defining the








In particular t1/2, which represents the time after whom the initial population is halved, is of great
importance for the nuclide selection in nuclear medicine. As we will show in the fourth chapter, the
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p, charged π 5
α, heavy ions 20
n 2.5÷21
Table 1.1: Typical values of wR. [3]
concentration of a (radio)pharmaceutical in a tissue follows a similar decay trend due to the biological
elimination of the “foreign” substance.
Let us now focus on dosimetry, the branch of medical physics that studies the effects of ionizing
radiation on organic (or organic-like1) matter. The most general physical quantity in this sector is the
absorbed dose, corresponding to the energy released by the incident radiation per mass unit. Again,





However, even though it would already be an appropriate indicator for this work, which does not
include clinical analyses but only dosimetric predictions, this quantity shows some limits; as a matter
of fact, no information is provided about neither the nature of the radiation nor the radiosensitivity of
the irradiated tissue. Another factor which is not considered by the absorbed dose is the irradiation
time, but trivially if an absorbed dose D is reached in 1 s rather than in 1 h, the tissue’s response
could become slightly different, as the cells would have less time to repair eventual sublethal damage
in their DNA (dose-rate effect).
In order to solve the first two problems, mostly in the radiation protection sector two variants of the
absorbed dose are used. The equivalent dose is defined as the absorbed dose multiplied by a weighting
factor wR associated to the type of radiation R; assuming that a volume is irradiated by different





where D and H indicate the absorbed and equivalent doses. In the same way, one can append another








Typical values of the weighting factors wR and human wT are reported in Tables 1.1 and 1.2. Since
these factors are dimensionless, the equivalent and effective doses maintain the same dimensions as the
absorbed one, i.e. those of an energy divided by a mass, but in order to distinguish them a different SI
unit is formally used instead of the gray: the sievert, Sv. Anyway, as already said, using just activity
and absorbed dose will be enough in our context. [3] [4] [5]
1.2 Radiobiology
This section’s goal is to describe briefly and qualitatively the mechanism laying under the cellular
damage caused by an incident ionizing radiation. When a ray hits a cell, the energy deposition inside
it generates a plenty of free radicals and reactive oxygen species, like hydroxyl groups and peroxides,
which are highly reactive and difficult for the cell to dispose of. The situation worsens if the radia-
tion hits and mutilates DNA in the cell nucleus: even though the cell is generally capable to repair
damages affecting just one DNA strand by reading the complementary information contained in the
1As we will se, water often represents a good approximation for some biological tissues.
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Human tissues wT
Bone marrow, colon, lung, stomach, breast, remainder tissues (6) 0.12
Gonads (1) 0.08
Urinary bladder, esophagus, liver, thyroid (4) 0.04
Bone surface, brain, salivary glands, skin (4) 0.01
Total (15) 1
Table 1.2: Typical values of human wT ; the nomenclature remainder tissues includes: adrenals, extrathoracic
region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, prostate (male), small
intestine, spleen, thymus and uterus/cervix (female); the number of organs in each group is in brackets. [3]
other one, a high concentration of free radicals can interfere and hinder this process; moreover, if the
incoming radiation mutilates both strands in the same positions, repairing without errors becomes
almost impossible. These situations then lead to chromosomal aberrations, which can result lethal for
the cell itself at the division stage.
It is clear that the intracellular concentration of oxygen plays an important role in the cell response
to radiation, as the indirect damage induced by free radicals are estimated to contribute to about 2/3
of the total; experimentally, hypoxic2 cells (e.g. certain kinds of tumour) show increased resistance to
radiation with respect to oxygenated ones. Such effect can be quantified through the so-called oxygen
enhancement ratio, OER = Dhyp/Doxy, which is an index comparing the absorbed dose required by
populations of hypoxic and aerated cells to attain the same damage quantified in cell death, or the
same surviving fraction.
In addition to cell death, which can be practically considered as a deterministic effect of radiation
happening when a certain threshold of absorbed dose is overtaken, from a medical and radioprotec-
tion point of view one must take into account the stochastic mutation effects; such events have no
threshold and can lead to serious pathologies like cancers, cataract or heritable diseases (if germ cells
are interested), their incidence increasing linearly with the absorbed dose. For this reasons, in every
branch of medical physics involving ionizing radiation, it is always fundamental to avoid or at least to
minimize the risks resulting from events hitting healthy tissues. [4] [5]
1.3 Therapy
The chance of curing cancer by means of ionizing radiation is one of the greatest results of applied
physics and is probably in the forefront of today’s scientific and technological progress. Mankind
discovered that ionizing radiations may have a therapeutic effect by the end of the XIX century, when
the Austrian surgeon Leopold Freund managed to remove a hairy mass from a patient by using X-rays
in 1896. In the following decades, such treatments were extended to more dangerous tumours and
embraced different kinds of radiation sources. Nowadays, there are several therapies adopted to treat
diverse types of cancers; at the most general level, we can identify two approaches: External Beam
Radiation Therapy (EBRT) and Internal Radiation Therapy (IRT).
EBRT makes use of beams especially of X-rays or electrons, but therapies with neutrons, protons or
heavy ions — constituting the so-called hadron therapy — are as well available in a limited number
of infrastructures all around the world. The mechanism of these therapeutic procedures is to hit a
localized tumour exactly where the energy loss of the incident particles is maximized; as an indicator
of it, we can define the stopping power, S, as the opposite space derivative along the beam direction




In fact, for each kind of radiation, the stopping power shows a maximum that may correspond to dif-
ferent levels of penetration along x, depending on the particle species, on its energy and on the density
2Presenting hypoxia, i.e. lack of oxygen.
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Figure 1.1: Examples of dose-depth curves of incident X, e− and p rays; the p curve shows Bragg’s peak. [6]
and composition of the material. Generally, electrons and photons lose most of their energy next to
the surface of incidence, while protons and other charged ions show a quite sharp peak, called Bragg’s
peak, just before the energy gets completely lost, hence at higher depths (Figure 1.1). In conclusion,
medical physicists and radiotherapists have the chance to choose among several fashions of therapies
with different particles at different energies, in order to assess the best treatment for any localized
cancer. Of course, it is fundamental to obtain stopping power peaks which are as sharp as possible
and to lower the rest of the S(x) curve, in order to avoid dose deposition on the surrounding healthy
tissues as far as possible; this is achievable by accurately creating monochromatic beams by means
of scattering foils or magnetic fields. Furthermore, narrowing the beams with collimators prevents
excessive lateral scattering. Modern techniques permit to select a treatment starting from the dose
requirement and producing an adequate beam; this is the case of Intensity Modulated Radiotherapy
(IMRT), which allows to irradiate the patient from different directions, and Image Guided Radiother-
apy (IGRT), which exploits the morphological information provided by an associated imaging tool.
Concerning IRT, the first method we are exposing is brachytherapy (or endocurietherapy after Marie
and Pierre Curie). It was the first invented IRT, dating back to the early 1900s, and consists in placing
directly a radioactive source inside the oncological patient; this is possible in two modes:
 intracavitary brachytherapy, positioning the radiation source in cavities next to the tumour
(common strategy for cervical, prostate and esophageal cancer);
 interstitial brachytherapy, inserting the source just inside the cancer, using radioactive needles
or wires.
Obviously, these methods are again referred to localized cancers and provide a high dose only to the
immediate source surroundings. But is it possible for radiation to act even on diffused tumours?
With γ-emitting radiotracers, as we will see in the next section, one can localize a cancer through
molecular receptors. Similar mechanisms can be extended as well to therapeutic radionuclides with α,
β− or Auger radiation, and in fact another kind of IRT, called Target Radionuclide Therapy (TRT),
Radiopharmaceutical Therapy (RPT) or Molecular Radiotherapy (MRT), is currently developing and
is considered very promising. Due to its huge relevance in this thesis work, TRT deserves a more
detailed description that will be offered in the following paragraph. [7]
1.3.1 Target Radionuclide Therapy (TRT)
As anticipated, several species of radioactive nuclei can be administered to the patients, either orally
or intravenously; they have to be bound to more or less complex molecules, whose task is to transport
the nuclei towards and into the target organs. The first radionuclide to be ever injected in a living
thing for scientific or medical purposes was 212Pb, used as a radiotracer in 1923 by the Hungarian
radiochemist George de Havesy during his researches on the metabolic processes of the plant Vicia
faba (vulgarly broad bean); his studies were awarded with the Nobel Prize in Chemistry in 1943.
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Radiation Em R LET Examples of emitters
α 3÷ 6 MeV 28÷ 100µm 80÷ 240 keV/µm 211At, 223Ra, 225Ac
β 0.1÷ 2.2 MeV 2÷ 10 mm 0.1÷ 1 keV/µm 90Y, 131I, 177Lu
Auger 1÷ 10 keV < 5µm 4÷ 26 keV/µm 111In, 123I, 125I
Table 1.3: General features of the radiations used in TRT. [4]
Figure 1.2: Illustration of α, β− and Auger e− ranges for TRT in bone tissue. [8]
The very first target therapeutic treatment on a human patient instead dates back to 1941, when the
American doctor Saul Hertz cured a patient suffering from Graves’ disease, a form of hyperthyroidism,
with a mixture of 130I and 131I; later, in 1951, radioactive 131I-NaI was approved by the Food and
Drug Administration (FDA), and it may be also considered the first theranostic3 radionuclide, since it
combines a β− radiation, usable in therapy, with a following γ emission, suitable as radiotracer, when
decaying to its isobar 131Xe; with both properties, one can monitor if the dose is being released in
the correct sites and how much. Anyway, theranostic radiopharmaceuticals can also contain different
isotopes or even different elements, having separate therapeutic and diagnostic contributions.
In conditions of hyperthyroidism, one can exploit the huge concentration of sodium in the ill thyroid
and the simple ionic bond between sodium and iodine to take the radioactive drug into the organ;
however, different pathologies may need different radionuclides to be treated effectively, together with
molecules suitable to bring them to their final destination. As for the nuclides, at least two main
features must be taken into account: the mean emission energy Em, which is strictly connected to the
dose that will be absorbed by the organic tissues, and the half-life, which has to guarantee that the
radionuclide does not decay immediately after its production but also that it will not stay for too much
time in the patient’s body; typical half-life values range from a few hours to a few days. Furthermore,
a short radiation range R is usually required in therapy to accompany the high degree of selectivity
reached by the carrier molecules and avoid rays escaping to healthy tissues. Finally, the linear energy
transfer LET = dE(l)dl , defined as the energy absorbed by the medium per unit path length l — similar
to the stopping power but evaluated from the material’s (and not the radiation’s) point of view —
plays an important role since it determines the effectiveness of the radiation in damaging the DNA of
the cancer cells.
Finally, Table 1.3 reports the main features of the emissions used in TRT; as we can see, α and Auger
particles show higher LET and lower R with respect to β, which are anyway more energetic than Auger
electrons. Some radioisotopes, mostly α-emitters such as 225Ac, generate radioactive daughters that
can present therapeutic effects themselves. We can notice as well that the Auger range is comparable
with the cell diameter, therefore it is necessary for an Auger treatment to bring the radionuclides
3Or theragnostic: both therapeutic and diagnostic.
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Figure 1.3: The three anatomical planes: transverse, coronal and sagittal. [10]
inside the nuclear membrane or at least inside the cell; once there, a single nucleus can emit up to
a few dozens of e−. A particular behavior belongs to the β+ decay: due to the annihilation of the
emitted positron with an electron, it generates in most cases a couple of collinear photons which make
β+ suitable for diagnostic and theranostic applications. [4]
1.4 Diagnostics
Medical physics is present in several sectors of medicine beyond oncology, if one considers the plenty
of diagnostic technologies we can rely on nowadays, for instance in orthopedics or in gynecology;
very simply, the possibility to look inside the patient’s body and obtain morphological and functional
information without physically opening it has been playing a revolutionary role in modern medicine.
The methods used in the daily routine of our hospitals involve Nuclear Magnetic Resonance (NMR),
ultrasounds and infrared imaging, but in this work our attention must be focused on the techniques
exploiting ionizing radiations and descending from the traditional X-ray radiography, i.e. CT, SPECT
and PET, since they can be used in order to achieve dosimetric calculation.
1.4.1 Radiography
The first medical application of X-rays was historically radiography, invented by the British doctor
John Hall-Edwards in 1896, just one year after the X-rays were discovered by Wilhelm Röntgen. Its
working principle is the following. An X-ray tube accelerates electrons emitted from a cathode filament
by thermionic emission towards an anode made of heavy metals; when these projectiles collide with
the anode, X-rays are produced by Bremsstrahlung or by orbital transitions following e− e− scattering.
Part of this radiation passes through a window, gets adequately filtered and reaches the patient’s body.
Now, if we call I0 the initial intensity of X-ray beam, when penetrating in a tissue along direction x
it will decrease as
I(x) = I0 e
−µx (1.10)
where µ represents the linear attenuation coefficient and depends on the tissue and on the incident
energy. Image receptors, like traditional films or modern detectors, positioned on the other side of the
patient, reveal the intensity getting out of the body and reconstruct a 2D image whose brightness is
proportional to the registered µ. Filtering is really important not only to obtain a clean signal but
also because the lower energies would never leave the patient’s body, just resulting in useless ionizing
radiation dose; in order to achieve a high degree of cleanness, an anti-scatter grid is also placed between
patient and detector. The evolution of this method has brought technologies such as fluoroscopy, which
allows a real time visualization of the interesting body region, angiography, permitting to see the blood
8
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Figure 1.4: Basic working principle of the CT scan. [9]
vessels thanks to a radiopaque4 contrast agent, mammography and of course CT. [9]
1.4.2 Computed Tomography (CT)
Like classic radiography, CT uses X-rays and provides morphological images of the patient’s body,
but this time in 3D. The underlying concept of tomographic reconstruction was formalized by the
Austrian mathematician Johann Radon in 1917, but developed at medical level only in 1972 by the
British engineer Godfrey Hounsfield and the South African physicist Allan MacLeod Cormack (winners
of the Nobel Prize in Physiology or Medicine in 1979). Its strategy is to produce a series of sliced
images (“tomography” comes from the Greek words tómos, “slice”, and gráphó, “writing”) lying on
one of the three anatomical planes (Figure 1.3), usually the transverse one, using external planar X-ray
beams from multiple directions around the body. Figure 1.4 schematically represents the essence of
the CT working principle.
From a mathematical point of view, processing the acquired data is not immediate, since we are
interested now in a more precise assessment of the linear attenuation coefficient µ = µ(x, y) as a
function of the scanning plane. Let us call θ the scanning angle, for whom it will be sufficient to be
θ ∈ [0, π) to avoid redundant information, and r the proper spatial coordinate of the scan (see Figure
1.5). The imaging process gives us a set of intensity profiles, one for each θ: calling L the scanning
line corresponding to (θ, r) and ds its infinitesimal line element, one has
Iθ(r) = I0 e
−
∫
L µ(x,y) ds (1.11)
from which one can find the total attenuation profiles, namely






µ(x, y) ds (1.12)
To make sense, we need a new frame of reference for µ(x, y); we can choose the r coordinate and
the new s coordinate, perpendicular to r and parallel to L (see again Figure 1.5, where L can be
assimilated to the AB segment). It is easy to see that the frame (r, s) differs from (x, y) by a rotation
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4With the property of absorbing X-rays.
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Figure 1.5: Reference frames used in a tomographic reconstruction. [11]




µ(r cos θ − s sin θ, r sin θ + s cos θ) ds (1.15)
The complete set of all the pθ(r) projections is called sinogram, whereas pθ(r) is also indicated as the
Radon transform of the function µ, R[µ(x, y)]. However, what we are looking for is µ(x, y), thus we
need a strategy to evaluate the Radon anti-transform
µ(x, y) = R−1[pθ(r)](x, y) (1.16)
The projection-slice theorem can help us to perform this calculation, as it states that the 1D Fourier






is equivalent to the 2D Fourier transform of the unprojected function µ(x, y)





µ(x, y) e−2πi(kxx+kyy) dx dy (1.18)
being kx = k cos θ and ky = k sin θ. If the latter identities for kx and ky hold, one can check that,
applying them in Eq. 1.18 and changing the coordinates (x, y)→ (r, s), Eq. 1.17 can be obtained (note
that the determinant of the transformation matrix is equal to 1).
Therefore, if we compute F1[pθ(r)] in a polar grid for all the (θ, r) couples available by our CT device,





= µ(x, y) (1.19)
After this back-projection process, which can be accomplished by means of several algorithms and
filters, the result is a detailed, highly defined (resolution even better than 1 mm of pixel size) 2D
image in the form of a matrix. Repeating this operation for more slices, one builds a 3D tensor
(specific formats are used, like the DICOM files, dcm), whose elementary cells take the name of
voxels. The coefficients stored in the voxels are traditionally the Hounsfield units, defined as
HU = 1000 · µ− µw
µw − µa
(1.20)
where µ, µw and µa are respectively the linear attenuations of the assigned voxel, water and air (µa
is actually very close to 0 and is often neglected) for the radiation used. [9]
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Figure 1.6: Essential schema of the SPECT working principle. [14]
1.4.3 Single Photon Emission Computed Tomography (SPECT)
After viewing the morphological imaging methods that will be used in this study, a short introduction
to functional imaging techniques exploiting ionizing radiations is necessary. The purpose of a functional
analysis is to provide, rather than anatomical details, information about the behavior of certain organs
or tissues. For instance, the methods we are going to expose allow to locate tumour masses amongst
the patient’s body. They are enormously important in this research for two reasons:
 they can be combined with morphological imaging in order to carry out dosimetric assessments;
 one of the goals of the ISOLPHARM project is to produce radiopharmaceuticals suitable for
this kind of analyses.
Like in TRT, the radionuclides used for diagnosis should have a half-life of at least some hours and not
longer than a few days. The molecular transport mechanisms are basically the same, with the drug
binding the target and irradiating, but a big difference regards the radiation that can be used, which
must be traceable and is typically γ. As a matter of fact, γ-rays are way more penetrating than the
other emissions, hence they deposit less energy in the patient and have by far a higher probability to
exit and reach the detectors. As said at the end of the TRT paragraph, also β+ decays are accepted
in these field because of the consequent e+ e− → 2γ annihilation. The earliest technique following
this principles was scintigraphy, born in the ’50s, which provides 2D images by collecting γ decays
in the so-called γ-camera, a device containing collimators (to ensure that the counted events come
exclusively from the desired direction), scintillation detectors and photomultipliers.
SPECT imaging was invented in 1962 by David Edmund Kuhl, an American doctor specialized in
nuclear medicine. Multiple γ-cameras are placed all around the patient similarly to the CT case,
but this time, since radiation comes from the inside, an angle of 2π must be covered (Figure 1.6).
Like in CT, a 2D sinogram is built, but a simple back-projection reconstruction is no longer precise
enough, due to the uncertainty on the emitting position. To solve such a problem, the Maximum Like-
lihood – Expectation Maximization (MLEM) method has been developed; this procedure, formalized
by Dempster, Laird and Rubin in 1976, follows a Bayesian approach and iteratively maximizes the
probability for the image to be correct if a given value is measured. The iterative formula yielding the











where cij represents the probability for the pixel Λj to contribute to the sinogram bin i and qi is the
number of counts in i. Repeating the process for subsequent planes one finally arrives to a voxelized
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Figure 1.7: Essential schema of the PET working principle. [14]
3D image.
Obviously, also in SPECT imaging one has to face the different attenuations of the biological tissues, as
γ radiation is not 100% penetrating, especially in dense materials like bones or teeth. The information
needed is gained from preliminary tests with external sources, as well as from CT images: in the
latter case, we can talk about hybrid SPECT/CT imaging, for whom an attenuation correction can
be managed taking the µ values directly from the Hounsfield units. Finally, since we are actually
discretizing a continuous distribution, an application of the Nyquist-Shannon sampling theorem for
signal processing sets a lower limit for the number of angular detecting positions n around the patient:




The most used pure γ-emitter in this sector is certainly 99mTc, a metastable nucleus decaying to its
ground state (g.s.) 99Tc with t1/2 = 6.0072 h and Em = 142.6836 keV. Another example, that will
return later, is 111In, undergoing electron capture (EC) in t1/2 = 2.8047 d towards the stable nuclide
111Cd, which de-excites with an appreciable γ radiation in the 100 ÷ 300 keV window, optimal for
radiodiagnostics. [4] [9] [12]
1.4.4 Positron Emission Tomography (PET)
Another phenomenon which can be exploited in order to achieve functional diagnostic tests is the
positron emission by β+ decay; this is what happens in PET imaging, that was developed in different
stages from the early ’50s to the middle of the ’70s. The main, big advantage with respect to SPECT
is that the annihilation occurring between the emitted e+ and an e− from the surrounding matter
produces a collinear couple of photons with the same energy of 511 keV. Such collinearity permits to
evaluate 2γ coincidences instead of single photons and, therefore, to avoid collimators and significantly
increase the efficiency of the signal collection (Figure 1.7). Another advantage is the possibility, for
the same reason, to use not just 2D but also 3D PET devices, as coincidences only depend on the time
interval ∆t between the two counts and can be detected even in two different slices; 3D instruments,
characterized by the absence of septa between contiguous slices, provide higher efficiency but also
more noise and more random coincidences. The image reconstruction is usually obtained by back-
projection, but other algorithms such as MLEM can be used, too; like for SPECT, an attenuation
correction is required and hybrid PET/CT and PET/NMR imaging systems have been developed. An
example of common radioisotope — and probably the most common so far — for PET applications is
certainly 18F which, decaying β+ to stable 18O with t1/2 = 109.77 min, is widely used in this branch
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of nuclear medicine.
Coincidences can be handled using the following formula for the rate Rc of random coincidences
between two detectors counting respectively C1 and C2 events per second: Rc = 2τC1C2, where
τ indicates the proper time window of the detectors, whose order of magnitude is typically 10 ns.
Random coincidences come from two (nearly) simultaneous events that lose a γ each in the patient and
are fallacious. Multiple coincidences, i.e. simultaneous events with no γ loss, and scatter coincidences,
i.e. when at least one γ is scattered but anyhow reaches a detector, can instead be considered. State-
of-the-art technologies use particular scintillating crystals with very fast response in order to measure
the time of flight (TOF) of the coincident photons and, knowing their speed is c, estimate directly
the position of the annihilation event5: this technique, that allows to inject even less activity in the
patient, is known as TOF PET.
Eventually, it is important to remark that CT, SPECT and PET devices have been developed not
just for clinical use but also for pre-clinical studies on animal — murine — samples. Smaller organ
dimensions are involved in these experiments, so the highest resolutions reachable are necessary to
visualize well defined results. A wide use of such images will be made in the next chapters. [4] [9] [12]
5Which is next to the β+ decay position due to the short range of e+ in a macroscopic scale.
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This work has been commissioned by the ISOLPHARM (ISOL technique for radioPHARMaceuticals)
project headed by the Legnaro National Laboratory (LNL) of the Italian National Institute for Nu-
clear Physics (INFN). ISOLPHARM was born in 2016 with the purpose of exploiting the II generation
ISOL facility SPES (Selective Production of Exotic Species) at LNL in order to obtain innovative ra-
dionuclides of medical interest with high purity. Being a strongly multidisciplinary collaboration, it
requires several kinds of professionists from different fields, such as physicists, engineers, biologists
and chemists. Besides INFN, many institutions are taking part to the experiments, like the Univer-
sity of Padova with the Department of Physics and Astronomy “Galileo Galilei”, the Department of
Chemistry and the Department of Pharmaceutical and Pharmacological Sciences.
The project is subdivided in three main tasks:
 Task 1, carrying on the experiments of nuclear physics and the development of the ISOL targets
and extraction technologies;
 Task 2, studying the chemical processes to isolate the radionuclides without losing pureness and
synthesize the radiopharmaceuticals;
 Task 3, including the biological testing of the new radiopharmaceuticals in vitro and in vivo.
Furthermore, up to now, two pilot experiments have been running:
 ISOLPHARM Ag (2018-2019), with the aim of producing by neutron capture small quantities
of 111Ag, which — as we will see — is probably the most innovative radionuclide obtainable by
means of the ISOL technique, and preliminarily studying its properties;
 ISOLPHARM-EIRA (2020-2022), meant to begin the in vitro and in vivo sperimentation.
The current chapter will mainly focus on the physical part and on the interesting radionuclides, before
finally giving a precise collocation to this thesis work inside the whole project. [1]
Figure 2.1: INFN-LNL and ISOLPHARM official logos. [1]
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(a) (b)
Figure 2.2: (a) ISOL-SPES explanatory schema. (b) Surface Ionization Source. [13]
2.1 The ISOL technique
As we were saying, the ISOL (Isotope Separation On-Line) method has been chosen in order to pro-
duce the radionuclides, since it allows to generate the RIBs (Radioactive Ion Beams) with a high level
of selectivity. The strategy consists in hitting a solid target with a proton beam accelerated by a
cyclotron; typical values of energy and intensity of this beam are tens of MeV and tens or hundreds of
µA. The nuclear reactions happening in the target produce a great variety of exotic nuclei, depending
on the target composition and on the proton energy. The most important target for ISOLPHARM
is a fissile (i.e. admitting nuclear fission reactions) target made up by seven uranium carbide disks,
whose diameter and thickness are 40 mm and 0.8 mm. Uranium carbide is a mixture of uranium
dicarbide (UC2), graphite (C) and, in lower concentration, uranium monocarbide (UC); due to its
heterogeneity, it is often referred to as UCx. Figure 2.3 shows which region of Segrè’s chart can be
populated with UCx. Examples of non-fissile targets under study are instead titanium carbide (TiC),
zirconium germanide (ZrGe) and gadolinium boride (GdB4).
The obtained nuclides diffuse all over the target and, since the temperature reaches (and is main-
tained at) 2000°C, the elements which are volatile1 in these conditions evaporate and effuse through
a structure called transfer line. Such line leads them to an ionizing high vacuum chamber, kept at a
pressure of about 10−6 ÷ 10−5 mbar. In the chamber the nuclides get ionized to the +1 charge state
and become ready to be extracted and accelerated by means of a high voltage that can reach 40 kV,
thus generating the RIBs. Actually, not every nuclide arrives to the accelerator: each mentioned stage
owns a proper efficiency depending on the atomic species. Hence, one can assign to each element a
coefficient ε given by the product of the contributions in efficiency for each process. These coefficients
are influenced by the geometry of the production target and by the selected ionization source. In the
context of SPES-ISOLPHARM, the studied sources are:
 SIS (Surface Ion Source), developed for the elements in the first two groups of the periodic table;
it consists of a 34 mm long tubular cavity with a diameter of 4.1 mm, able to achieve temperatures
of 2000÷2200°C by means of Joule effect and to ionize elements with ionization potential up to
7 eV once they interact with the surface (a schematic representation of ISOL-SPES and a SIS
are shown in Figure 2.2);
 PIS (Plasma Ion Source), for elements characterized by higher electronegativity; classifiable as
a FEBIAD (Forced Electron Beam Induced Arc Discharge) source, it is mainly composed by a
tantalum cathode, a molybdenum anode and a cylindric discharge chamber, surrounded by a
solenoid originating a magnetic field; the cathode, heated by Joule effect until 2200°C, generates
a thermionic emission of electrons which are gathered by the anode (the electrodes having a
150 V voltage between each other) and injected in the chamber, forming a plasma that can be
accelerated by the magnetic field and sent towards the neutral nuclides passing by in order to
1Otherwise they are referred to as refractory.
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Figure 2.3: Regions of the nuclide chart that can be populated starting from a target in UCx and production
efficiency with a proton beam at 40 MeV and 200 µA. [14]
ionize them.
 LIS (Laser Ion Source) is currently under study; atoms can be ionized by an incident laser and,
for each radionuclide of interest, the laser wavelength optimizing this process can be investigated.
It is important to underline how reaching a high temperature is fundamental for the correct func-
tioning of the entire apparatus: to achieve this, the choice of the incident beam’s features and of
the materials composing the production target must maximize the power dissipated by the nuclear
reactions. Contextually, a cooling system is required for the ionizing high vacuum chamber and, for
certain types of targets, even for the target itself. In order to attain this, a cooling system exploiting
the thermal conduction of water and liquid litium is utilized.
In conclusion, the ISOL technique results convenient since it allows to obtain high quantities of different
radionuclides and, changing the composition of the target, to focus the production in several regions
of the nuclide chart, opening the possibility to study even unconventional radioisotopes, which may be
difficult and/or too expensive to be produced using ordinary accelerators or nuclear reactors. [13] [14]
2.2 The ISOLPHARM chain
After the ISOL stage we have just described, once the chosen radionuclides are ionized with a certain
efficiency, it is possible to accelerate them by means of an electric field, sending a RIB towards a
mass selector. Here, the nuclei are distinguished depending on their mass number, which affects their
deflection angle and thus their flight trajectory. The resulting isobaric RIB, containing just the nuclide
of interest and its isobars, is finally deposited into a collection target. This selection stage is expected
to be highly reliable, with ε ∼ 100%. A part of the isobars can decay towards the interesting one, e.g.
when handling chains of β-emitters moving diagonally along the nuclide chart, but anyway a chemical
treatment is needed in order to attain a satisfactory purification. Subsequently, the pure radionuclide
is bound to a carrier molecule, obtaining the radiolabelled drug. Such molecule can be divided in
three components (Figure 2.4):
 the chelator, that stably binds the radionuclide with coordination covalent bonds;
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Figure 2.4: Targeting mechanism and structural subdivision of a radiopharmaceutical carrier molecule. [14]
Figure 2.5: Representation of the complete ISOLPHARM radiopharmaceutical production chain. [14]
 the targeting agent, whose function is to take the radionuclide to (or into) the cancer cells
interacting with specific receptors overexpressed in their plasma membrane;
 the linker, or spacer, which connects the previous two and avoids interactions between them.
Before being commercialized, such radiopharmaceuticals have to undergo a series of in vitro and in
vivo experiments in order to test if they distribute correctly in the ill sites, if they irradiate those
tissues with an appropriate dose and how much they damage healthy organs. An exhaustive schema
which summarizes all the explained processes is visible in Figure 2.5. [14]
2.2.1 Innovative radiolabelling
Let us now have a short look at the main candidate radionuclides that could be produced by the
ISOLPHARM project (Figure 2.6), highlighting the features that make them eligible for a medical
use. The most important nuclide studied up to now is 111Ag. Such silver isotope has never been used
in medical physics because of the difficulties and the costs to face in its production, whereas the ISOL
technique with the use of the UCx target would solve these issues; however, it decays β
− with a mean
energy of Eβ = 360.4 keV — suitable for cancer therapy — and with a half-life of t1/2 = 7.45 d — not
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Figure 2.6: Main radioisotopes of actual or possible medical interest producible with the ISOL technique. [14]
too short to be transported to the hospitals and not too long-living in the patient’s body —. Moreover,
as we will see later, the de-excitation of its daughter nucleus 111Cd emits a γ radiation which could
make a drug radiolabelled with 111Ag traceable, hence perhaps leading to a fully theranostic effect.
Regarding its isobars, 111Ag belongs to a chain of β− unstable nuclei which start from the neutron
drip line and, with increasing half-lives, approach the valley of stability of the Segrè chart until the
stable isotope 111Cd. Due to the decays and the chemical properties of the elements involved, the
collection target will just receive 111Cd, 111Ag and a small contribution of its mother nucleus 111Pd,
decaying with t1/2 = 23.4 min and presenting a metastable state,
111mPd, with t1/2 = 5.5 h. Analytic
calculation of the activity attainable in the collection target can be performed by solving Bateman’s
differential equations [15] [16].
The ISOL technique combined with an UCx target can produce pure β
−-emitters as well, suitable
for therapy, such as 89Sr and 90Y; these isotopes are characterized by an intense β− emission (the
latter has Eβ = 932.4 keV) and a negligible γ radiation once decayed. Other important obtainable
radionuclides are 131I, 136Cs and 153Sm, that show a lower β− energy with respect to the pure β−-
emitters but an appreciable γ radiation which might be used for SPECT diagnosis. Among these
radioisotopes, together with 111Ag, 136Cs assumes as well a special relevance for the ISOLPHARM
collaboration since its medical use is still in the early stages and the high volatility of cesium ensures
that great quantities of it could successfully be extracted from the production target. [12] [13] [14] [15]
2.3 Purposes
In this context, the aim of such a work is to establish a connection between the physical and the
biological tasks of the ISOLPHARM project, starting a new series of studies of the same kind. In-
struments and notions taken from nuclear, medical and biological physics will be exploited in order
to build a computational predictive model for the dose absorbed by the biological tissues of a murine
sample during a TRT using innovative radiopharmaceuticals.
More specifically, two powerful tools will characterize this work in the following chapters:
 Monte Carlo simulations, provided by the Geant4 software [2], developed at CERN and widespread
among research in physics of the fundamental interactions, which will be used to simulate the
effects of radiation for a high number of decay events;
 medical PET/CT and SPECT/CT combined imaging, which will give information about the
activity distribution and the morphology of the murine body.
This computational dosimetry study will be carried out in the next chapters with two different ap-
proaches. The first one, in Chapter 3, will use Monte Carlo simulations to examine the effectiveness of
either monoenergetic or radioisotopic radiation in small biological volumes and then this information
will be added to the PET or SPECT imaging in order to estimate the absorbed dose maps; we will
see how this is possible computationally by following a convolution procedure. The second method,
instead, consists in a direct Monte Carlo based dosimetry, which runs the simulations directly in a
computer reproduction of the mouse’s body — the so-called phantom — built from the CT and uses,
again, the functional PET or SPECT imaging for the decay events; this strategy, together with an
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Figure 2.7: Geant4 official logo. [2]
analytic model for the biodistribution of the activity provided by means of biophysical arguments, will







Dosimetry with MIRD schema
As well-known, the Monte Carlo principle consists in simulating a high number of stochastic events
in order to extract the behavior of a physical system. The first method we are going to use for dose
calculation exploits Monte Carlo simulations to study the behavior of a radiation source in a material
in terms of deposited energy at a certain distance. The technique is then based on a computational
procedure of convolution and on medical physics imaging, in particular emission tomography tools
which can provide information about an activity distribution. The first section of this chapter will
expose in detail the adopted schema and, once all the main aspects will be clarified, it will explain
how they will participate to the current research.
3.1 The MIRD formalism
This method was proposed by the Committee on Medical Internal Radiation Dose (MIRD) of the
American Society of Nuclear Medicine & Molecular Imaging (SNMMI) and, for this reason, it is
known as MIRD schema [17]; its strategy includes four main steps.
1. The creation of a virtual volume made of a given material or tissue, subdivided in elementary
units such as concentric shells or voxels (in Geant4, they can be classified as sensitive volumes
in order to count the deposited energy).
2. The collocation of a radiation source inside the volume, paying attention to its symmetries.
3. The Monte Carlo simulation of a high number of time-independent radiation events, followed by
the calculation of the mean absorbed dose per event in every shell (Dose Point Kernel, DPK)
or voxel (Voxel S-Value, VSV).
4. The convolution between the obtained kernel and a function expressing the activity distribution
in the sample, namely a PET or SPECT 3D image.
Let us now focus for a while on the meaning of such a convolution operation, considering the voxel
case. First of all, it is important to understand that, from a physical point of view, VSVs and DPKs
represent a tensor kernel, whose coefficients are connected to the effectiveness of a source emitting
from its center. Our sample will correspond to a voxelized volume with the dimensions and resolution
of the image; the kernel used must have the same voxel size. Following the time-independent MIRD
Figure 3.1: Basic concept of the MIRD schema; of course every target voxel may be itself a source voxel. [4]
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Figure 3.2: Spherical volume with 5 concentric shells of water created with Geant4 (radial planes have been
drawn just to ease the 3D view and do not represent any border between surfaces); a quarter is missing in order
to visualize the shells.
formulation under the assumption that the masses involved do not change during the irradiation, we




A(rs, t)S(rt ← rs) (3.1)
where S(rt ← rs) is the S-value in rt given by the kernel centered in the voxel rs and A(rs, t) indicates
the activity in rs provided by the image.
1 A more rigorous definition of the S-value in rt for a
radioactive source placed in rs can be given as follows: calling mt the mass of rt, Ei the mean energy
of the ith decay mode, Yi its branching ratio and φ(rt ← rs, Ei) the average fraction of Ei deposited
in rt, one has





Ei Yi φ(rt ← rs, Ei) (3.2)
Repeating for the whole sample, or for a single organ, the final result is a 3D dose rate map; the
implementation of more kernels referring to different tissues (e.g. with the help of a CT) leads to more
precise estimations. If a series of subsequent PET or SPECT images is available, one can reconstruct
the activity curve and integrate over a period T , obtaining the time-integrated activity
Ã(rs, T ) =
∫ T
0
A(rs, t) dt (3.3)
and finally the total absorbed dose after T
D(rt, T ) =
∑
s
Ã(rs, T )S(rt ← rs) (3.4)
Of course the integration over T could also be applied to the dose rate Ḋ, but this would require to
apply a convolution for each image instead of only once.
The purpose of this chapter is then to provide a database, validated by the comparison with the pre-
existing literature, containing the DPKs and the VSVs of the ISOLPHARM radionuclides of interest
for several tissues and voxel sizes. Finally, an example of VSV convolution using a murine sample will
be proposed. DPK convolution is possible as well by means of additional calculation, but this will not
be done in this context even if the coefficients will be inserted in the database.
3.2 Dose Point Kernels (DPK)
Let us begin this study with the DPKs. On Geant4 one can build a spherical volume subdivided in
concentric shells, as in Figure 3.2(a), and fill it with a selected material. The first simulations will run
with monoenergetic and isotropic e− sources in order to become familiar with the model and see if
1The indices s and t stand for source and target.
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Particles Cut-off range [mm]
γ, n 1
e 0.1
p, π, µ 0.05
α, 3He 0.01
Ions 0.001
Table 3.1: Typical cut-off ranges in the Electromagnetic Standard Option 3 library; 1 mm is the default value
in Geant4. [2]
Figure 3.3: Monoenergetic electron source at 500 keV in water, on the left, and compact bone, on the right;
yellow and green trajectories represent electrons and photons respectively.
it is reliable and in accordance with the references; then, a method to assess the uncertainty of such
Monte Carlo simulations will be proposed. Subsequently, radioactive sources will be inserted and the
effectiveness of some of the main ISOLPHARM radionuclides will be studied. Due to the spherical
symmetry of the volumes, the sources will always be placed in their center.
For DPKs, two materials were used: water and compact bone. Water is often utilized in this field as a
good approximation for most of the human soft tissues because of its hydrogen and oxygen composition
and its density ρw = 1 g/cm
3; moreover, many studies of microdosimetry in literature, concerning
either simulations or experiments, make use of water in this context. All the materials simulated in
this research activity, here and in the following chapter, are available on the Geant4 material database
but can be also generated manually by the user.
Regarding particle interactions and nuclear reactions in Geant4, the chosen library was the physics list
Electromagnetic Standard Option 3, developed especially for applications of nuclear physics requiring
high precision on low energy processes involving electrons, hadrons and ions. An interesting parameter
is the cut-off range: in order to lighten the computational mole, particles get killed (i.e. they cease
to be traced in the Monte Carlo) when their energy falls below a certain threshold, which is related
to a penetration range in the material they are going through; otherwise, if this does not happen,
a particle is normally killed when it gets out of the simulation world, i.e. an air box containing the
sphere. Table 3.1 shows the cut-off ranges of the cited physics list for the main particles involved in
our simulations. To enable decays the list Radioactive Decay Physics was added.
3.2.1 Monoenergetic electron sources
For this first part, e− sources with energy E0 of 10, 50, 100 and 500 keV were considered and the
reference study was Botta et al., 2011 [18], where a different Monte Carlo code, FLUKA [19], was used.
Figure 3.3 illustrates two equal spheres made of water and compact bone with a monochromatic source
of e− at 500 keV located in their centers. We can immediately notice a different degree of penetration
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E0 [keV] dr [µm] ρRcsda|w [g/cm2] ρRcsda|cb [g/cm2]
500 20 1.766 · 10−1 1.898 · 10−1
100 2 1.431 · 10−2 1.545 · 10−2
50 0.6 4.320 · 10−3 4.681 · 10−3
10 0.04 2.515 · 10−4 2.761 · 10−4
Table 3.2: Shell thickness and e− range in water and compact bone [21] used at the various energies.
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Figure 3.4: (a) DPK curves of 500 keV e− in water using Geant4 with 106 events, compared with Botta et al.,
2011 using FLUKA. (b) Residuals plot.
due to the higher density of compact bone, namely ρcb = 1.85 g/cm
3; moreover, intuitively, a radiation
with lower energy results less penetrating: for this reason, in order to obtain precise curves, 100 shells
with equal thickness dr were always created, as in literature, with dr decreasing for lower energies.
The radius of the sphere, clearly obtainable multiplying dr by 100, was always long enough to contain
at least all the non-γ trajectories.
The results of the first simulation, with e− at 500 keV in water and compact bone, are shown in
Figures 3.4 and 3.5 (all the graphs were produced by means of the Python3 software [20]). The curves
obtained with Geant4 are compared to the ones obtained by FLUKA in Botta et al., 2011; in order to
facilitate this comparison, the same units were used. Defining the radiation range Rcsda as the particle
path in the material before losing all its energy in the Continuous Slowing Down Approximation,
where the energy loss is considered equal to the stopping power of the material:
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Figure 3.5: (a) DPK curves of 500 keV e− in compact bone using Geant4 with 106 events, compared with Botta
et al., 2011 using FLUKA. (b) Residuals plot.
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Figure 3.6: Convergence study for DPKs with e− at 500 keV in water.
 in the abscissa the external radius of each shell r is expressed in mm;
 in the ordinate we find a dose-like quantity defined as the ratio E/E0, being E the energy
deposited in the shell and E0 the initial energy, divided by dr/Rcsda.
The Rcsda values, shown in Table 3.2 together with dr, were taken from the NIST estar database [21].
Anyway, the DPKs in our database are simply expressed in keV/g per event. At E0 = 500 keV we
notice a substantial agreement with the reference study, as visible also in the residuals plots. Like we
expected, the compact bone curve appears sharper than the water one, since they both go to zero near
their own ranges; the spherical shells used in the simulations were exactly the same, hence we can see
that, contrary to water, compact bone absorbs almost all the radiation within half the total radius.
A thing that could already be done with this first results is finding a method to estimate the uncertainty
of this calculation and, especially, to have an idea of how many events we need to simulate for reliable
results. With this purpose, let us now have a look at the convergence study in Figure 3.6; graph
(a) compares six simulations of 500 keV electrons in water with the number of events growing from
103 to 108. One can immediately distinguish the poor quality of simulations with a small number of
events and the nearly total absence of noise in the 108 case. Thus, we can assume the latter as our
model and calculate the percentage residuals of the other simulations with respect to it, in graph (b);
the final step is then to compute the percentage standard deviation of each simulation with less than
108 events, as in graph (c). In our case, we may be interested in having fluctuations below 1% until
Rcsda is reached; looking at these plots, we find out that such a precision with respect to the highest
statistics of 108 events is achieved by at least 106 events. A simulation of this kind takes about 10
min with CPU Intel i5-9600 (6) @ 4.6 GHz, which is of course an acceptable time (the upper abscissa
in the last graph shows a rough estimate of the computational time based on this measured value);
for this reason, all the other simulations in the current section will be characterized by 106 events.
Since radioactive sources have complex radiation spectra and are consequently more time-expensive
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Figure 3.7: DPK curves of 100 keV e− in (a) water and (b) compact bone using Geant4 with 106 events,
compared with Botta et al., 2011 using FLUKA.
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Figure 3.8: DPK curves of 50 keV e− in (a) water and (b) compact bone using Geant4 with 106 events, compared
with Botta et al., 2011 using FLUKA.
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Figure 3.9: DPK curves of 10 keV e− in (a) water and (b) compact bone using Geant4 with 106 events, compared
with Botta et al., 2011 using FLUKA.
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Figure 3.10: DPK curves of 131I in (a) water and (b) compact bone using Geant4 with 107 events, compared
with Papadimitroulas et al., 2011 using GATE and Graves et al., 2019 using MCNP. (c) Residuals plot for
water. (d) 131I decay scheme [27].
to a computer, these considerations will be applied again in the following sections.
The first examined E0 gave a quite good result if compared with literature; however, if we consider
Figures 3.7, 3.8 and 3.9, the agreement worsens for lower values of E0. This could be due to some
differences in the two Monte Carlo algorithms, such as different cut-off settings or other parameters.
Also, the version of FLUKA used is at least 10 years old and more recent updates may have added
some improvements. Anyway, what matters is that the energy deposition pattern is basically the same
and we can proceed with the next simulations.
3.2.2 Radioactive sources
After observing the results of the monochromatic e− DPKs, we are ready to study radioisotopic
sources. An important difference from the previous case is that γ radiation assumes more relevance
now, since we are analyzing heterogeneous nuclear emissions. This is why the Geant4 sphere needs
to be enlarged: 200 shells were set with progressively growing thickness for a total radius of 402 mm.
Increasing thickness was chosen as a compromise between the small volumes required to have a precise
assessment of β radiation and the computational trouble deriving from a too high number of sensitive
shells. With dr0 = 0.02 mm the thickness of the first shell (i.e. the radius of the central core), the i
th
shell was i · dr0 thick. Dealing with the reference literature, the studies consulted for this DPK calcu-
lation were Papadimitroulas et al., 2012 [22] and Graves et al., 2019 [23], who used respectively the
Monte Carlo codes GATE [24], which is actually an user-friendly interface of Geant4, and MCNP [25];
such works employed different shell thicknesses as well. Another pertinent and extremely recent paper
belongs to Mendes et al., 2021 [26].
Let us begin with the case of 131I, since it is the most studied in literature among the radionuclides of
our interest. We are talking about a β−-emitter from whose decay we anyway expect a consistent γ
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Figure 3.11: Convergence study for DPKs of 131I in water.
radiation due to the de-excitation of its daughter 131Xe. From Figure 3.10, we immediately recognize
two shoulders corresponding to the low-range β− and high-range γ emissions. This time the ordinate
plots the absorbed dose (expressed in keV/g) multiplied by the squared distance r2. Such a visual-
ization mode, common in literature, highlights the fact that for photons there is a plateau as long as
the deposited energy per shell goes like dE ∝ dr, since in these conditions dE/dm ∝ dr/(r2dr) = r−2.
From Figure 3.10(b) we deduce that, such as in the monoenergetic e− case, the shape of the curve
does not depend on the material crossed: compact bone shows just a faster absorption of the β−
contribution than water. Dealing with literature, we notice a very good agreement in the whole γ
shoulder and in the β− one after 1 mm, while the part below 1 mm reveals different interpretations
even from the two references themselves; the residuals plot for water in Figure 3.10(c) shows that
Geant4 has a wide percentage difference in lack or excess from the references at the shortest distances,
while the discrepancy at long distance is due to zero approaching. Since this issue appear to be proper
of the physics libraries used by the Monte Carlo codes, a substitution of the adopted one with the list
Electromagnetic Livermore Physics was tried, but no significant improvements were registered. On
the other hand, the differences occurring from 2 mm on seem really small.
107 decay events were simulated, and this decision was again supported by a convergence study; the
three steps are illustrated in Figure 3.11, where we can see a different trend with respect to the previ-
ous situation. Looking again for an uncertainty under 1% with respect to 108 events, the choice fell on
107 for all the simulations of this type; 106 was no more enough to guarantee that, due to the longer
radius covered by these simulations. The CPU time became ∼ 100 min (depending on the nuclide)
with our devices, but it was anyway acceptable since such kernels have to be calculated just once.
Now we are focusing on a powerful instrument characterizing codes like Geant4 and MCNP: the pos-
sibility to program manually the particle killing. One can kill all the produced particles of a certain
species, for example all photons, in order to compute exclusively the other contributions. Obviously,
removing a particle species speeds up the simulations: this is why neutrinos, typically produced in β
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Gamma + electron DPKs, Cs-136 in water
Geant4
MCNP (Graves, 2019), 
MCNP (Graves, 2019), e
Figure 3.12: (a) DPK total curve of 136Cs in water using Geant4 with 107 events, compared with Graves et al.,
2019 using MCNP. (b) β curve. (c) γ plus Auger and internal conversion curve.
decays but not interacting with matter, can be neglected and killed.
To provide an example of this, let us switch radionuclide to 136Cs: producible by ISOLPHARM in high
quantities, low energy β− emitter (mainly Eβ < 100 keV), it however emits a considerable γ radiation,
with the brighter ray appearing in almost all decays with energy Eγ = 818.514 keV [12]. In Figure
3.12(a) we can see the comparison of the total curve with Graves et al., 2019: again, the reference is
higher at shorter distances, but this time there is also a difference where the two components meet.
As visible in Figure 3.12(b), where only the β− rays are considered, there is a noticeable disagreement
between the Monte Carlo codes when simulating this particular radiation. Moving instead to Figure
3.12(c), we realize that γ rays alone are not enough to reproduce the radiation if the β− electrons are
missing, but one can not neglect the effectiveness of other e− coming from Auger emission or internal
conversion (the curve colored in lime). Anyhow, for β−-emitters this contribution usually hides under
the β− dose. In conclusion, the observable discrepancies derive from a different interpretation of the
β− component, while other e− and γ find a good agreement.
We might now dwell on the behavior of our most representative radionuclide, 111Ag, whose proper-
ties have already been discussed. Figure 3.13 illustrates its DPK total curve simulated with Geant4
together with its two components β and γ (actually γ plus Auger and internal conversion). Since this
isotope has not been used in nuclear medicine yet, its literature is poor: we only found a γ curve in
Graves et al., 2019, which in Figure 3.13(b) is compared to our γ and non-β electrons.
Another interesting radionuclide is an isobar of the previous one, namely 111In, whose γ radiation was
already described when talking about SPECT imaging. However, it appeared as well in Table 1.3 as an
Auger e− emitter used in TRT, and in fact in Figure 3.14(a) both Geant4 and Papadimitroulas et al.,
2012 show an irregular left shoulder which may describe this Auger radiation; looking also at Figure
3.14(b), which represents the same situation but in compact bone instead of water, three main humps
are visible before the γ shoulder, meaning that at least three different e− ranges are contributing.
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Figure 3.13: (a) DPK total curve of 111Ag in water using Geant4 with 107 events. (b) γ plus Auger and internal
conversion curve compared with γ curve from Graves et al., 2019 using MCNP. (c) 111Ag decay scheme [28].
Finally, Figure 3.15 reports the results for 90Y, a pure β−-emitter whose average Eβ exceeds 900 keV.
γ emissions are very rare for this radionuclide and in fact its γ shoulder presents values about one
order of magnitude smaller than 111Ag, two orders smaller than 131I and 111In and three orders smaller
than the best γ-emitter we have seen so far, i.e. 136Cs. The agreement with Papadimitroulas et al.,
2012 looks good especially in water (Figure 3.15(a)) and is probably the best up to now.
We conclude illustrating other radioactive sources of medical interest — here placed in water but
available in compact bone as well in the DPK dataset — having an equivalent study in Papadim-
itroulas et al., 2012; these nuclides, represented in Figures 3.16 and 3.17, are 68Ga, 99mTc, 153Sm and
177Lu. The Geant4 curves, mostly in the γ part, match quite well with the reference except for 99mTc
(Figure 3.16(b)), where a possible explanation is that GATE may have had some trouble simulating
a metastable state: the β− shoulder, belonging to the g.s., seems indeed correct, but the γ side is
way too low for a common and widely used γ-emitter like this. Other DPK curves obtained from
radionuclides of medical interest — 18F, 64Cu and 89Sr — are reported in Appendix A.
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Total DPKs, In-111 in compact bone
Geant4
GATE (Papadimitroulas, 2012)
Figure 3.14: DPK total curve of 111In in (a) water and (b) compact bone using Geant4 with 107 events, compared
with Papadimitroulas et al., 2012 using GATE.
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Total DPKs, Y-90 in compact bone
Geant4
GATE (Papadimitroulas, 2012)
Figure 3.15: DPK total curve of 90Y in (a) water and (b) compact bone using Geant4 with 107 events, compared
with Papadimitroulas et al., 2012 using GATE.
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Total DPKs, Tc-99m in water
Geant4
GATE (Papadimitroulas, 2012)
Figure 3.16: DPK total curve of (a) 68Ga and (b) 99mTc in water using Geant4 with 107 events, compared with
Papadimitroulas et al., 2012 using GATE.
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Total DPKs, Lu-177 in water
Geant4
GATE (Papadimitroulas, 2012)
Figure 3.17: DPK total curve of (a) 153Sm and (b) 177Lu in water using Geant4 with 107 events, compared with
Papadimitroulas et al., 2012 using GATE.
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(a) (b)
Figure 3.18: (a) Geant4 voxel-made cube with central source. (b) Source placed in a vertex.
3.3 Voxel S-Values (VSV)
Once completed the DPK part of the dataset, which will contain DPKs for all the mentioned nuclides
both in water and compact bone, we are ready to move in the voxelized world that will host nearly all
the remaining work from now on. The reason for that, as learned in Chapter 1, is that every medical
image handled — CT, PET or SPECT — will be made of voxels. We can already point out that VSVs
will not reach the same granularity at short range as the DPKs, since it is convenient for the former
to have the same voxel size as the emission tomographies in order to convolve properly: typical voxel
sizes in medical physics belong to the order of magnitude of 1 mm, for clinical imaging, or 0.1 mm,
for pre-clinical studies on mice, whereas with DPK we reached about 0.01 mm in the inner shells.
As what matters is the dose at a certain distance from the source, this time the symmetry of the
volume plays a more important role. One may intuitively think that, once built a virtual cube with an
odd number of voxels N in its size, the central voxel should be chosen as source, like in Figure 3.18(a).
However, this is not the best way to approach the problem, because it does not maximize the number
of accessible distances from the source. Let us make a trivial example: if the source is centered, the
eight vertices will stay exactly at the same distance from it, and this length — half the diagonal —
will also be the maximum reachable. Instead, putting the source in a vertex, as in Figure 3.18(b),
would unlock the access to several higher distances: considering again the vertices for simplicity and
referring to a voxel in space using its own center, one will have
 the source voxel itself, at zero distance;
 three voxels with distance equal to the cube size, L = (N − 1) dx with dx being the voxel size;2
 three voxels with distance equal to the diagonal of a face,
√
2L;
 one voxel, the one on the opposite vertex, with distance equal to the diagonal of the cube, that
will also be the farthest,
√
L2 + 2L2 =
√
3L.
Furthermore, there is no more need to set an odd N . In conclusion, putting the source in a vertex
allows to simulate the same distances as a cube almost3 eight times bigger, with a great saving of
both computational time and memory. The price to pay is a bit of statistics, since now each distance
except zero has a lower multiplicity4, but simulations with many events will not significantly suffer
from this issue.
As also found in the reference studies Lanconelli et al., 2012 [29] and Amato et al., 2013 [30], since
in a real medical voxelized image one does not know the exact position of the source inside a voxel,
the decay events in the simulation should be uniformly distributed in the voxel volume. Besides the
mentioned papers, which used respectively the Monte Carlo code DOSXYZnrc [31] and a previous
release of Geant4, other valuable references are Pacilio et al., 2009 [32] and Lee et al., 2017 [33].
2If we have e.g. N = 3 voxels in a row, the distance from the center of first to the center of the third will be 2 · dx.
3The three slices containing the source voxel can not be repeated.
4It is averaged on a lower number of voxels.
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Figure 3.19: Convergence study for VSVs of 131I in soft tissue; N = 6, dx = 3 mm.
It is clear that, placing the source in a vertex, a consistent part of the decay events will exit from
the sensitive volume (1/2 of the total directly from the source voxel, since it has three internal and
three external faces and the emission is isotropic). The outer world, initially composed by air, was
turned into the same material of the cube in order to evaluate if there was a significant contribution
of backscattered particles returning in. The result was practically identical, so the outer world was
set to void in order not to waste computational time in tracing gone particles.
Dealing with VSVs, the ISOLPHARM database has the following features:
 it contains all the nuclides for whom the DPKs have been calculated;
 the materials used are compact bone and soft tissue (ρst = 1.03 g/cm
3), a generic compound
approximating all the human soft tissues, chosen instead of water to better match with the
pre-existing literature;
 the voxel size represents a variable as well: all the nuclides were simulated with dx = 2.21
mm and dx = 3 mm, which are typical parameters of clinical imaging devices, and with the
pre-clinical value dx = 0.5 mm;
 N = 6 was adopted for every simulation.
For these simulations a 0.01 mm cut-off range was set for e and γ, as CPU time did not significantly
increase. Occasionally, the most innovative nuclides such as 111Ag may have also kernels computed in
lung tissue and at higher clinical dx (5 mm and 9.28 mm); a complete summary of the VSV database
content is inserted in Table 3.3. This time the plots will simply show absorbed dose in keV/g versus
distance in mm.
Once again, 131I is present in both references and will be used as a pilot radionuclide, as well as in
the usual convergence study, illustrated in Figure 3.19. Like for the radioisotopic DPKs, we choose
107 events that in this case would keep the fluctuations below about 2% with respect to the highest
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dx 18F 64Cu 68Ga 89Sr 90Y 99mTc 111Ag 111In 131I 136Cs 153Sm 177Lu
0.50 mm s,b,l s,b s,b s,b s,b s,b s,b s,b,l s,b s,b s,b s,b
2.21 mm s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b
3.00 mm s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b s,b
5.00 mm s,b s,b
9.28 mm s,b s,b
Table 3.3: All the material and dx combinations contained by the VSV part of the database; the letters s,b,l
stand for soft tissue, bone and lung.
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Figure 3.20: (a) VSV curve of 131I in soft tissue using Geant4, compared with Lanconelli et al., 2012 using
DOSXYZnrc and Amato et al., 2013 using Geant4; N = 6, dx = 3 mm. (b) Residuals plot.
statistics of 108. From the VSVs in Figure 3.20(a) we can see again a steep slope β− shoulder and a
slight slope γ; the agreement between the three curves looks excellent, whereas the residuals in Figure
3.20(b) say that the difference between the two releases of Geant4 is higher with respect to this study
and DOSXYZnrc.
Passing to 111Ag, which in this case was completely absent from literature, we can observe the behavior
of the VSVs under variation of tissue, as in Figure 3.21(a), and of voxel size, as in Figure 3.21(b); it is
clear that in the latter case we can expect very different values in the first voxels, as dx becomes way
longer than the average range Rcsda of the β
− electrons emitted by 111Ag, which is about 1 mm [21].
This means that volume and mass go like dx3, while the radiation core increases very slowly after
Rcsda, assigning lower doses to bigger voxels.
Now, since the previous section instilled some doubts about the coefficients of 99mTc, we can proceed
with Figure 3.21(c); surprisingly, we notice that the disagreement has moved from the γ shoulder to
the β−. Actually, a possible explanation might be that the reference, contrary to this research, did
not include the subsequent β− decay from 99Tc to the stable isobar 99Ru; so literature, whose β−
curve is one order of magnitude smaller, may be representing just the internal conversions and Auger
emissions of the metastable state, that compete against photons with branching ratio ∼ 11%. Under
this assumption, what matters to us is that the γ side agrees perfectly, corroborating the hypothesis
of GATE dysfunction we made in the previous section for 99mTc. Anyway, the decision to kill the g.s.
in the simulation makes sense, since it has not the same half-life as the metastable: it is actually much
longer, tg1/2 = 2.111 · 10
5 y versus tm1/2 = 6.0072 h [12], so a real situation would be hardly affected
by its contribution. The best choice for a VSV database would probably be to simulate both states
separately, as the information about the activity of 99mTc provided by SPECT can be renormalized
to 99Tc and one may perform two subsequent convolutions to reproduce the real situation; a simple
model on how to do this will be developed in Appendix B.
Figure 3.21(d) shows instead a pre-clinical VSV example for 18F — the most common radionuclide in
PET, as stated in Chapter 1 — with dx = 0.5 mm; those VSVs will be useful in the next section for
the convolution. Two pure β−-emitters (89Sr and 90Y) and two heavier nuclei (153Sm and 177Lu) are
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Voxelized dosimetry (0.5 mm), F-18 in soft tissue
Geant4
Figure 3.21: (a) VSV curves of 111Ag in soft tissue and compact bone using Geant4; N = 6, dx = 2.21 mm. (b)
VSV curves of 111Ag in soft tissue using Geant4 at different values of dx.(c) VSV curve of 99mTc in soft tissue
using Geant4, compared with Amato et al., 2013; N = 6, dx = 3 mm. (d) VSV curve of 18F in soft tissue using
Geant4 at the pre-clinical voxel size of dx = 0.5 mm.
then treated in Figure 3.22:
 the former demonstrate an excellent agreement in the β− shoulder, eased by the high statistics
descending from the high Eβ (about 600 and 900 keV) that generates a lot of secondary e
−; for
the same reason, having poor statistics, the γ side presents a certain level of noise;
 the latter agree very well with Lanconelli et al., 2012, whereas there is an underestimate of the
γ contribution with respect to Amato et al., 2013, probably due to the older release of Geant4
used in that study.
Finally, a summarizing point of view is offered in Figure 3.23, where all twelve investigated radionu-
clides are compared to each other. If we proceed focusing on the therapeutic β radiation, the most
energetic nuclei are of course the two pure β−-emitters mentioned a little while ago, together with
68Ga. Such nuclide, a β+-emitter suitable for PET and already employed in nuclear medicine, is very
particular because it unites an amount of photons comparable to 18F to a massive energy deposition
in the first few mm from the source; naturally, these features make it really powerful from a thera-
nostic point of view. After these three, we find our most interesting candidate, 111Ag. Its radiation
appears very similar to the one of 177Lu but with a higher energy release from the β− particle (see
the thick lines in the graph); 177Lu is currently used in cancer therapy even with theranostic appli-
cation [34], therefore if the ISOLPHARM goal of producing radiopharmaceuticals labelled with 111Ag
will be accomplished, there is no reason not to think that, in the future, such radiolabelled drugs could
be approved for theranostics by the national and international agencies. Then all the other nuclides
follow until the last one, 111In, which is obviously the least energetic since it is the only one not to
undergo any β decay.
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Figure 3.22: VSV curves of (a) 89Sr, (b) 90Y, (c) 153Sm and (d) 177Lu in soft tissue using Geant4, compared
with Lanconelli et al., 2012 using DOSXYZnrc and Amato et al., 2013 using Geant4; N = 6, dx = 3 mm.


































Figure 3.23: VSV curves of all the nuclides of interest in soft tissue using Geant4; N = 6, dx = 3 mm.
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Figure 3.24: Scientific publications dealing with β−-emitters in TRT in the latest years. [35]
We conclude by showing Figure 3.24, that displays the latest research trend of β−-emitters in TRT;
the employment of 177Lu is constantly growing, so we might hypothesize that a similar role could be
played by 111Ag in the future.
3.4 Convolution
Now that the VSV database has been built, it may be useful to provide a demonstration of how it
can work. The convolution operation could reveal itself computationally very expensive if applied to
an emission tomography, as ordinary numbers of voxels in such a 3D image are, considering just the
order of magnitude, 102 × 102 × 102, corresponding to ∼ 106 voxels. Fortunately, one can speed up
the counts recurring to the Fourier transforms, which can turn the convolution into a simpler product
in the following way.
The convolution theorem states that the Fourier transform of the convolution between two functions
is equal to the pointwise product of their transforms, namely
F[A ∗ S] = F[A] · F[S] (3.5)
where A and S stand for our functions of activity and S-values, ∗ represents the convolution as
previously defined and · is the pointwise product. It is then sufficient to apply the inverse Fourier
transform to both members to see that





which is the exactly the equation we were searching for. A discrete F must be used due to the discrete
nature of our objects. All these operations can be done using the FFT (Fast Fourier Transform)
functions available on the Python3 library Numpy and take just a few seconds.
Of course, to show an example we need an image: the one we are going to use comes from a pre-clinical
hybrid PET/CT imaging of a mouse, performed at INFN Southern National Laboratory (LNS) with
the γ emission of the radiolabelled drug 18F-FDG. FDG stands for fluorodeoxyglucose, i.e. a glucose
analog containing a fluorine atom which can obviously be a radioisotope. The resolution is 0.5 mm
for both PET and CT, so the VSV kernel to use is precisely the one reported in Figure 3.21(d).
Figure 3.25 shows, in the upper row, the superimposed PET/CT of the mouse; CT is represented in
greyscale in the background, as it will always be from here on, whereas the red and yellow colormap
represents the activity per voxel volume (in kBq/mL) provided by the PET. The numbers around the
graphs represent the number of voxels in the three dimensions (originally 148 × 160 × 160 but some
empty slices were cut to speed up the counts); our kernel has N = 6, so an equal tensor having the
VSVs in its 11 × 11 × 11 core was built. We should dwell for a while on this view, which first of
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Figure 3.25: Upper row: 18F-FDG PET/CT image of LNS mouse in the three anatomical planes. Lower row:
dose rate map computed by convolution in the 100% soft tissue approximation.
all allows us to face what is happening in the murine body. The brighter zones in the upper coronal
and sagittal planes correspond more or less to the mouse’s shoulders, i.e. the region where usually
tumours are inserted in pre-clinical experiments; a high concentration of glucose is expected in cancer
masses, so a great amount of radiopharmaceutical should be found there. The other bright spot in
the lower body corresponds instead to the urinary bladder; such an organ is also expected to contain
a lot of activity, being the final collector of the excretory system which gradually removes undesired
substances like FDG; naturally, depending on the PET acquisition time, the urinary bladder can be
found more or less filled with radioactive urine due to urination. Finally, the grey objects around the
mouse are clearly part of the instrumentation.
As our first try, let us work under the approximation that the whole phantom is composed by soft
tissue. If a convolution between the PET activity and the 18F VSVs at dx = 0.5 mm is performed,
one obtains the results displayed in the lower row of Figure 3.25, i.e. the dose rate in each voxel, here
expressed in mGy/s. The activity distribution is pretty much reflected in the dose rate map and in
fact, remembering the shape of our kernels, we can expect a higher deposition of energy right next
to the radiation sources. For completeness, an analogous convolution using the 18F DPKs in water
(which are visible in Figure A.1(a), Appendix A) has been performed. This was possible by means of a
conversion procedure that appended the DPK interpolated values to a 11× 11× 11 tensor kernel; this
tensor allowed to include most of the γ contribution, but also a bigger kernel could be used. The result
is displayed and compared with the VSV in soft tissue in Figure 3.26: neglecting the small discrepancy
between water and soft tissue, the dose rate distribution appears less peaked on the sources, probably
because, contrary to the tiny DPK core (dr0 = 0.02 mm), the size of the source voxel dx is comparable
to the average range of the β+ radiation of 18F in water, Rcsda ∼ 0.6 mm [21]. This means that VSVs
already reach their maximum dose at the shortest distance, whereas DPKs form a hump.
The approximation of 100% soft tissue is not so far from reality, but further attempts can be made
in order to improve this first result. For instance, using the masking tools provided by Python3, it is
possible to perform the convolution only on a region of the phantom: this means that one can convolve
different organs with the kernels calculated in the associated tissues. To do this, first of all, we have
to deal with the CT; as we will see, murine Hounsfield units in pre-clinical experiments often need a
calibration and one can not relate them a priori to a particular tissue. As this CT was not calibrated,
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Figure 3.26: Upper row: dose rate map of LNS mouse computed by DPK convolution in the 100% soft tissue
approximation. Lower row: difference between this dose rate and the VSV result.

























Soft tissue [−200, 2900]
Compact bone [2900, 32766]
Table 3.4: Hounsfield units intervals corresponding to the main tissues in LNS mouse.
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CT (0.5 mm), HU in [-3100, -200]



































Figure 3.28: CT with the window HU ∈ [−3100,−200], supposed to host the lungs, highlighted in red.
a Python3 tool was developed to approximately calibrate the HU by visualizing certain selected tissues
and assessing their HU window. It is important to underline that our current requirements imply that
also the CT must have a resolution of 0.5 mm to correctly execute the cuts with the masking tools.
However, 0.5 mm is not the best resolution for pre-clinical CT imaging, so the borders between organs
will not always be clear with this images, but we will try as well to isolate some organs.
It turned out that the Hounsfield units in our CT were staying in the interval HU ∈ [−17117, 32766].
The most important tissues to be identified are at least two, i.e. the farthest from the definition of
soft tissue:
 compact bone, which as we saw is denser than soft tissues;
 lung, expected to be less dense instead.
With our tool we are able to observe the distribution of the Hounsfield units, like in Figure 3.27,
investigate a particular HU interval, as in Figure 3.28 with lung, and calibrate the HU for the tissues
we are interested in (again Figure 3.27 with the colored regions and Table 3.4). As appearing from the
figures and the table, HU overlaps between different tissues are not unusual; we can see for instance
that the lung interval includes some other minor organs — maybe pancreas, deducing from the coronal
plane in Figure 3.28 — and part of the instrumentation, too. Of course in the histogram some peaks
may appear, but they do not have to be automatically associated to a particular tissue, due to overlaps
especially for soft organs and to the different volumes occupied by the tissues; bone, for instance, seems
to follow a shoulder trend rather than a sharp peak, since it is not present below HU = 2900.
With this information, it is possible to implement the cuts in our Python3 convolution procedure
just like in Figure 3.29, where the compact bone and lung masks are compared to the complete CT.
Both cuts include some fragments of intruder tissues due to overlaps or border effects; the latter
characterize the lung tissue since it always presents lower HU than the soft tissues and, when these
share a discontinuity with the outer (or sometimes inner) air, HU typical of the lung can be found.
As a matter of fact, in the lower row it seems like the mouse’s skin is made by lungs. Anyway, CT
images with lower dx together with methods to reach a much higher precision will be adopted in the
following chapter, where some of this problems will be solved.
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Figure 3.29: Full CT compared with the cuts of compact bone and lung in the three anatomical planes.











































100% soft tissue vs 3 materials






























































Figure 3.30: Upper row: dose rate map of LNS mouse computed by convolution in the 3 tissues (soft-bone-lung)
approximation. Lower row: difference between and the 100% soft tissue result and this dose rate.
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Since the aim of this section is just to give an example of how the MIRD schema works, we can finally
move to Figure 3.30, where the masks were applied to the convolution. Obviously, VSVs for 18F in
compact bone and lung were computed and added to the database. In the upper row we can visualize
some darker spots in the most radioactive zones due to the presence of bones; the lower row shows
the difference between the 100% soft tissue approximation and this case: as expected, there is a clear
hindrance in bones, since their density is quite higher and the absorbed dose is inversely proportional
to the mass where the energy is deposited. On the other hand, we do not appreciate substantial
variations in lungs probably because the Geant4 material database considers empty lungs, with no air
inside and density ρl = 1.04 g/cm
3, practically equivalent to the other soft tissues. We will look for a




The second technique of computed dosimetry that will be employed in this thesis can be simply
identified as Direct Monte Carlo. It is conceptually simpler than the MIRD schema — even though
the simulation part is heavier and more time-expensive — and it is expected to be more precise.
The common features with the MIRD formalism are the use of the Monte Carlo method, even if at
different levels, and the importance of PET or SPECT images to obtain information about the activity
distribution, as well as CT for the morphological characteristics of the sample. First of all, the method
will be introduced and then we will connect to the end of the previous chapter by applying the Direct
Monte Carlo dosimetry to the same phantom used there.
4.1 Working principle
This procedure is present in several published researches; as reference literature, we suggest the papers
Gupta et al., 2019 [36] and Pistone et al., 2020 [37]. The working principle is quite easy and consists
in the following main points.
1. Voxelized reproduction of the entire sample, including its material composition, by exploiting
the CT in a Monte Carlo software like Geant4.
2. Taking the activity from the PET or SPECT imaging in the sample as a probability distribution
for the Monte Carlo events.
3. Simulation of an arbitrary number of events to be later normalized or directly of the number of
events corresponding to the total activity in the PET or SPECT (Figure 4.1).
4. Collection in each voxel of the dose rate or, if the activity was cumulative, of the absorbed dose
in a time window.
Most of this steps, actually all apart from the first one, can be automatized by means of Geant4,
Python3 and ROOT [38] scripts. The construction of a sample corresponding to the CT requires
instead an accurate analysis of the Hounsfield units as we did in Section 3.4 and an appropriate
Figure 4.1: Direct Monte Carlo simulation on a murine phantom with the Geant4 interface GATE.
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Geant4 materials Composition Density [g/cm3]
Air N 76%, O 23%, C, Ar 0.00120479
Water H 67%, O 33% 1
Soft tissue ICRP O 60%, C 26%, H 11%, N, Na, P, S, Cl, K 1.03
Compact bone ICRU O 41%, C 28%, Ca 15%, P 7%, H 6%, N, Mg, S 1.85
Lung ICRP O 78%, H 11%, C 8%, N, Na, P, S, Cl, K 1.04
Lung MOBY O 74%, H 10%, C 10%, N, Ca, P 0.30
Table 4.1: Used materials from Geant4 with their density, composition and percentage fraction of the main
(> 5%) components. [2] [3] [39] [40]
handling of the 3D images, for example reading files in DICOM format with the software mentioned
above. We could focus for a while on this point, since up to now we talked about tissues from
the Geant4 material database without giving any further details in addition to density. It is now
worthwhile to introduce what it means to consider a material on Geant4.
The Geant4 software permits to build a virtual volume and fill it with a material. The composition
and density of this material are mimicked with the goal of reproducing in a reliable way the reactions
and the scattering of an incident radiation. A dataset of materials — from which we already took air,
water, compact bone, soft tissue and lung — is available in the user documentation. Anyway, there is
also the possibility to generate a material by oneself, providing the information about its density, its
ionization energy, its atomic components and their percentages. One can also find such information for
the tissues already appearing in the database. Table 4.1 shows the characteristics of the materials used
up to now, and adds an alternative definition of lung found in the user documentation of GATE. This
lung model, tagged as MOBY [40], comes from a set of 3D and 4D1 murine phantoms available on the
market in order to perform accurate simulations for pre-clinical experiments. Since it approximates a
proper murine lung instead of a human one, it may result convenient to use it, also to give a better
characterization of lungs, which should be less dense than soft tissues at least in a respiration average.
Anyway, we will still use lung ICRP in the next simulation in order to compare its dose rate map with
the convolution.
In conclusion, one should be able firstly to read the CT images accessing to their values in Hounsfield
units and develop an algorithm capable to assign correctly the corresponding materials to an empty
voxelized phantom. In the next example, the same HU intervals as in Chapter 3 (Table 3.4) will be
used, but later we will try to improve our strategy.
4.2 Comparison with MIRD schema
Now that the Direct Monte Carlo dosimetry procedure and the Geant4 definition of material have been
clarified, we can try and replicate the final results of Chapter 3 in order to compare the two techniques.
Simulations of 1.65 · 107 events, corresponding to the total activity in Bq measured by the PET, were
launched on the Geant4 interface GATE; practically, an instantaneous photograph of the dose rate
was obtained by running all the decays that occur in 1 s. In Figure 4.2, upper row, the dose rate map
obtained with the new method in the 100% soft tissue approximation is illustrated and, if we move
to the lower row, the difference between this map and the one computed by convolution in the same
approximation reveals a good agreement, with deviation below 10%. In particular, we observe that
the direct method tends to have a small excess of dose with respect to the other. This probably occurs
because the use of VSVs calculated with N = 6 means a tensor kernel with size 11× 11× 11 voxels,
i.e. for each source the information about what happens outside this cube gets lost; the brightest γ
radiations, such as the one following the β+ decay of 18F used here, should be affected by this behavior
more than short range emitters. A few voxels present also a negative difference, anyway really small,
probably due to fluctuations in the Monte Carlo.
Using the same mechanisms as before to assign the tissues to the sample’s voxels — i.e. roughly
1Including time effects like respiration and heartbeat.
46
CHAPTER 4. DIRECT MONTE CARLO 4.2. COMPARISON WITH MIRD SCHEMA
















Dose rate map with direct Monte Carlo


























Direct Monte Carlo vs MIRD schema
































































Figure 4.2: Upper row: dose rate map of LNS mouse computed by Direct Monte Carlo in the 100% soft tissue
approximation. Lower row: difference between this dose rate and its homologous obtained following the MIRD
schema.
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Figure 4.3: Upper row: dose rate map of LNS mouse computed by Direct Monte Carlo in the air-soft-bone-
lung approximation. Lower row: difference between this dose rate and its homologous (without air) obtained
following the MIRD schema.
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identifying all voxels having their Hounsfield units within a certain interval with the correspondent
material —, we proceed with the Direct Monte Carlo dosimetry in a phantom made of air, soft tissue,
compact bone and lung (ICRP). The material selection appeared to be easier on Geant4 rather than
on its interface GATE so, remembering that the underlying software is literally the same, we returned
to the main version of Geant4. Furthermore, error diagnostic is more comfortable and a higher number
of features can be controlled by the user. The first effort was made inserting air outside the mouse’s
body, where the Hounsfield units allowed it; however, in this way, huge amounts of dose rate appeared
in the air voxels, since the small deposited energy divided by the smaller air mass yielded divergent
values. This problem was solved by sending automatically to zero the dose rate in air, as we are
not interested in it. The results are represented in Figure 4.3, upper row. In the lower row this
simulation is compared with its homologous computed by the MIRD schema, which actually had soft
tissue instead of air. We can still see a border effect due to air just outside the mouse, where in fact
the convolution has higher values. Other discontinuity effects are visible inside the body; two main
issues may occur indeed in the MIRD schema:
 the radiation getting out from a tissue A and passing through another tissue B is not counted,
since different kernels undergo separate convolutions: Direct Monte Carlo may result higher in
B;
 in the case of a double discontinuity of the kind ABA, the dose from the first A layer can bypass
B and reach the second A layer: there, Direct Monte Carlo may be lower or higher depending
on the density of B with respect to A.
In conclusion, from this section it emerges that, when considering different tissues, the MIRD schema
might not reproduce the results as precisely as the Direct Monte Carlo dosimetry for the reasons
we have just underlined. The main advantage of the former method is computational time, namely
a few seconds versus about 100 min with CPU Intel i5-9600 (6) @ 4.6 GHz for a simulation of
this type (assuming to already have the convolution kernels), but, on the other hand, the latter
guarantees an undoubtedly higher precision. Thinking of what we are going to do next in this work,
the computational time of Direct Monte Carlo is certainly sustainable; therefore our decision is to
choose the second method for the remaining activities, whose goal is to provide a few indications
about how to theorize a radiopharmaceutical biodistribution in time and, using such a model, how to
integrate a dose rate over a time interval in order to finally obtain the absorbed dose.
4.3 Biodistribution model
This section will try to develop a reliable mathematical model for the time evolution of a radiopharma-
ceutical biodistribution mediated by transport kinetics. In particular, we are interested in the activity
in a region of interest (ROI) or volume of interest (VOI) — such as an organ, a tissue or a cancer —
after a time t from the injection. The following considerations are partially inspired by the works of
Shevtsova and Shevtsova, 2017 [41], Sato et al., 2021 [42] and Watabe et al., 2006 [43].
Let us imagine a system representing the whole murine or human body and subdivided into two
compartments:
 compartment 1, corresponding to the ROI;
 compartment 0, comprehending the rest of the body.
From a biological point of view, the key of this theoretical scaffold is the transport mechanism mediated
by the cell membrane. Suppose to inject a radiopharmaceutical intravenously: it will travel in blood
(compartment 0) until it binds a cell receptor of the ROI (compartment 1) or until it gets collected
by the excretory system for the elimination. Anyway, even in the ROI a certain number of drug
molecules per time unit will undergo the inverse process and return to compartment 1: a continuous
exchange happens, and it would go on indefinitely, if radioactive decay and biological expulsion did
not play their own roles. Hence, there are at least three physical and biophysical processes that must
be considered in the development of such a model:
48
CHAPTER 4. DIRECT MONTE CARLO 4.3. BIODISTRIBUTION MODEL
 the radioactive decay of the radionuclide, mediated by the disintegration constant λ;
 the radiopharmaceutical exchange between the compartments, modulated by the transition rates
0→1 and 1→0, which will be called h and k;
 the elimination of the radiopharmaceutical from compartment 1 due to the excretory system,
which collects it in the urinary bladder in order to expel it; the transition rate 0→elimination
will be referred to as l.
Like λ, the transition rates have the dimensions of an inverse time; such a characterization is typical
of Markov processes, i.e. stochastic processes where the transition between two states does not depend
on how the first state was reached. With these definitions, one can now write the following homoge-
neous linear system of differential equations with constant real coefficients, identifying the number of
radionuclides in the two compartments N0 and N1 at time t:
Ṅ0 = −(λ+ h+ l)N0 + kN1
Ṅ1 = hN0 − (λ+ k)N1
(N0(0), N1(0)) = (Nin, 0)
(4.1)
with λNin being the total injected activity (TIA). Summing over the compartments, we obtain the
behavior in the whole body:
Ṅ = Ṅ0 + Ṅ1 = −λ(N0 +N1)− lN0 = −λN − lN0 (4.2)













or simply, calling M the transition matrix,
~̇N = M ~N (4.4)
with the initial conditions of the Cauchy problem ~N(0). Its solution can be expressed as
~N(t) = etM ~N(0) = Φ(t)Φ(0)−1 ~N(0) (4.5)
with Φ(t) a solving matrix. Thus, in order to calculate etM we need to start from the eigenvalues τ of
M :
det(M − τI) = det
(
h′ − τ k
h k′ − τ
)
= (h′ − τ)(k′ − τ)− hk
= τ2 − (h′ + k′)τ + h′k′ − hk != 0
(4.6)
The discriminant of such a quadratic equation is
∆ = (h′ − k′)2 + 4hk (4.7)
and finally the determinant is equal to zero when
τ12 =





Notice that ∆ > 0 since the transition rates are ∈ [0,+∞) by definition, hence τ12 ∈ R. Finding the
eigenvectors related to a generic eigenvalue τ :(
h′ − τ k
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Note that τ1 − τ2 > 0 if at least one of the transition rates or the radioactive disintegration constant
is not zero, which is a necessary condition for our system to make sense.
Now, let us analyze our solution. First of all, we may point out that the equation for N0(t) is practically
useless at least to the current research, since we have not any interest in studying the activity in the
whole body but an organ. So, our attention must be focused on N1(t); the eigenvalues of the transition
matrix M , which now can be written in the extended form
M =
(




assume a fundamental role in the regulation of our biodistribution in a ROI. Looking at Eq. 4.8, we
immediately realize that τ2 < 0 when the system makes physical sense, as all its addends are negative,
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Figure 4.4: TRT-likely example of activity in a region of interest applying the biodistribution model; the
dashed lines represent separately the two exponential contributions. Parameters setting: a = 1 in arbitrary
units, b = 0.0001 s−1, c = 0.01 s−1.
thus the subtracted exponential is decreasing. What about τ1? We should check its sign, for example
investigating when τ1 ≥ 0:
τ1 =
h′ + k′ +
√




We can erase the 1/2 factor and subtract h′ + k′ to both members, getting√
(h′ − k′)2 + 4hk ≥ −h′ − k′ (4.19)
and, since the second member is always positive, we can square both members, obtaining


h′2 + k′2 − 2h′k′ + 4hk ≥

h′2 + k′2 + 2h′k′ (4.20)
and then
4(hk − h′k′) ≥ 0 (4.21)
At this point, we had better expand h′ and k′:
hk − λ2 − λk − λh−hk − kl ≥ 0 (4.22)
which is never true in the physical conditions of our system. In other words, we have just found
out that τ1 < 0 as well: we can state that the law regulating the concentration of a radionuclide
in a selected ROI is proportional to a difference between two negative exponentials with decaying
constants τ1 and τ2, where τ1 > τ2, corresponding to the eigenvalues of the transition matrix M as
defined before.
With a further step we can switch to activity by multiplying λ times, namely
A1(t) = λN1(t) = λNin
h
τ1 − τ2
(eτ1t − eτ2t) (4.23)
or equivalently, with a smarter notation,
A(t) = a(e−bt − e−ct) (4.24)
where a is directly proportional to the TIA, b = −τ1 and c = −τ2. A representative graph of this
situation is visible in Figure 4.4, where the initial conditions set were a = 1 in arbitrary units,
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b = 0.0001 s−1 and c = 0.01 s−1. Such values of b and c were chosen in order to visualize a typical
TRT trend. The blue curve illustrates the activity in the ROI: as expected, at t = 0 there is totally
no radiopharmaceutical arrived yet, but its amount soon increases, reaches a maximum and slowly
starts decaying; the dashed lines just show the two negative exponentials separately. This can lead to
a few considerations: while the c exponential is strongly involved in the initial growth of the curve,
the b contribution tends to approximate the decay for t → +∞; thus, a configuration with b  c is
desirable for a target organ. Anyway, it is more than a radioactive decay and in fact, if we analyze
the coefficients in detail, we discover that
b = −τ1 = −
h′ + k′ +
√
(h′ − k′)2 + 4hk
2
= −−2λ− h− k − l +
√
(λ+ k −λ− h− l)2 + 4hk
2
= λ+
h+ k + l −
√
(k − h− l)2 + 4hk
2
≡ λrad + λbio
(4.25)
In conclusion, in such systems, the radioactive decay expressed by λ ≡ λrad is combined with the so-
called biological decay, modulated by this new constant λbio depending on the transition rates between
the compartments and the elimination rate. Since b = −τ1 > 0 and λrad can be chosen arbitrarily
small (actually up to λrad = 0 in the non-radioactive case), one can easily demonstrate that λbio > 0.
An analogous argument can be applied to c, yielding c ≡ λrad + λ̄bio.
4.4 Dynamic imaging
Now, we can try to exploit our mathematical model for the biodistribution of a radiopharmaceutical.
In particular, since dose calculation is our priority, we could assume that, together with activity, also
the dose rate approximately follows a law of the kind
Ḋ(t) ∼ a(e−bt − e−ct) (4.26)
with the parameters a, b and c maintaining the same properties as before: a ∝ TIA and 0 < b < c.
In fact, as we have seen with the MIRD schema, to a first approximation the largest contribution to
the dose absorbed by a ROI is self-absorbed, although some events may penetrate from the external
body and generate a cross-absorbed contribution; the latter would be anyway a surface effect in a
volumetric context. If this assumption is fine and if we have several data to interpolate, then we will
be able to compute the absorbed dose by integration over a period T
D(T ) = a
∫ T
0



















and when T → +∞, which is not an unlikely possibility considering that the radiopharmaceutical









that will always be positive according to our restrictions for b and c. In order to apply this, we need
at least two things:
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Figure 4.5: AMIDE representation of the activity distribution (arbitrary units) after 2 h from the injection
of 111In-IP-001 in two BIOEMTECH mice; the coronal plane shows the upper mouse, whereas the transverse
section is upside down with respect to our dose maps.
 a series of PET or SPECT images at different moments after the injection;
 a higher precision in the tissue individuation to facilitate the dose calculation in a ROI.
This features will be achieved thanks to the supplementary material of a published study connected
to the ISOLPHARM project. Such a research, identified as Verona et al., 2021 [44], had the aim
of evaluating pre-clinically the reliability of a radiopharmaceutical containing 111In and capable to
bind the cholecystokinin-2 receptor (CCK-2R), overexpressed in the plasma membrane of several
cancer cells and poorly expressed by healthy cells. The radionuclide is bound to a 1,5-benzodiazepine-
derivative, forming the radiolabelled drug 111In-IP-001. As we already know, such a radioisotope is
suitable for SPECT imaging, and in fact we could count on a series of hybrid SPECT/CT images
distributed in time provided by the Greek group BIOEMTECH [45], specialized in molecular imaging
and collaborating with ISOLPHARM. Such data were acquired on a population of male adult mice
with a tumour mass stimulated on their right shoulder.
From a morphological point of view, the new CT images have a higher resolution than the one used
before — namely 0.2 mm versus 0.5 mm — and will allow a more precise definition of the borders
between tissues; this will be illustrated in detail in the next paragraph, where certain organs will be
selected and cut with different approaches. A better resolution implies a higher number of voxels, in
our case 600×350×350, that may put in trouble the volume construction in Geant4. For this reason,
exploiting the fact that Geant4 can easily center both the volume and the source distribution in its
proper reference frame, the CT images underwent some marginal cuts (obviously including only air
and instrumentation) in order to lighten the occupation of computational memory.
Regarding the time distribution, a SPECT/CT study of two mice together — having the names of
MX (upper mouse) and M16 (lower) — at 2, 4 and 8 h after the injection of 111In-IP-001 was chosen.
The resolution of the SPECT images was actually still 0.5 mm, for a total amount of 308× 125× 125
(2 h) or 307 × 125 × 125 (4 and 8 h) voxels, but this was not a problem as we decided to use a
Direct Monte Carlo approach rather than a series of tissue-dependent convolutions. Also the SPECT
images were cut at their farthest ends, because of the presence of a loud noise in activity despite the
complete absence of any living tissue in those regions. Figure 4.5 shows a representation, obtained
with the AMIDE toolkit [46], of the activity after 2 h from the intravenous injection of 111In-IP-001;
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Soft tissue [6000, 11000]
Instrumentation [10000, 12000]
Compact bone [11000, 65535]
Table 4.2: Hounsfield units intervals corresponding to the main tissues in BIOEMTECH mice.
the SPECT noise, then removed on Geant4, is still visible in the coronal and sagittal planes. We note
that this time the activity in the urinary bladder is way higher than in the rest of the mouse, and
particular cancer regions do not emerge.
Using this SPECT/CT series combined to Direct Monte Carlo, a dosimetry study can be performed.
We could begin with a calibration of the Hounsfied units, e.g. from the CT at 2 h, exactly like it was
done in Chapter 3 with the imaging from LNS. This time, they stay in a completely different window,
namely HU ∈ [0, 65535]; since from Eq. 1.20 we know that materials less dense than water, like air,
should have HU < 0, a different scale was probably set in this CT apparatus. Furthermore, the values
are distributed like in Figure 4.6, where two cuts were applied:
 to the air contribution, which is too big to be compared with the other tissues;
 to the bone tail, now including also teeth, that proceeds with sporadic counts until the maximum
HU value, bringing visualization issues.
As before, the selection of the tissues, reported in Table 4.2, was accomplished by a patient work
of visualization and assessment using highlighted pictures like Figures 4.8 and 4.7. Contrary to the
previous CT, instrumentation revealed higher values, in complete superimposition with bone and soft
tissue, probably due to the employment of denser materials. In these two figures, the organs appear
much better defined than before; the compact bone interval represents in an excellent way the murine
bones and teeth, whereas the lung window includes many border effects, but has the advantage to
avoid the involvement of heart and blood vessels in the rib cage, as visible mostly in the transverse
plane. As we anticipated, we will now adopt the MOBY definition of lung, hence expecting higher
dose rates in that ROI due to the lower density assumed. Anyway, we now have better instruments
than before and it would be a shame not to try a more precise attribution of the tissues to the virtual
phantom; the next paragraph will show what could be done.
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CT (0.2 mm), HU in [11000, 65535]



































Figure 4.7: CT with the window HU ∈ [11000, 65535], supposed to host bone, highlighted in red.
















CT (0.2 mm), HU in [4000, 6000]



































Figure 4.8: CT with the window HU ∈ [4000, 6000], supposed to host the lungs, highlighted in red.
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Figure 4.9: A frame from the lungs selection of mouse M16 using ImageJ.
4.4.1 Organ selection
Our current goal is to compute the absorbed dose in a time interval T by a ROI, but the results of
this paragraph will also allow us to perform a better Direct Monte Carlo simulation in general. In
fact, what we are going to do is selecting specific organs — remember that knowing the dose absorbed
by the healthy tissues is as important as the one absorbed by the cancer — in order to:
 assign them the correct tissue, avoiding to put it in wrong places;
 have a direct access to those organs when calculating the dose rate.
Unfortunately, the presence of organs with way different shapes, reciprocal positions and compositions
makes it very difficult to develop a common procedure to do it. For this reason, we will focus on two
organs which are considered representative of two different situations:
 the lungs will be the pilot case for organs of whatever shape identified by a specific HU window
which is in partial or total overlap with other tissues;
 the brain will represent instead organs whose borders are well-defined by a discontinuity in the
Hounsfield units, which in this case corresponds to the compact bone of the skull.
Starting from the lungs, the work to do is simpler and in our case it is strongly needed also at the
beginning of the simulation, in order to delete the border effects visible in Figure 4.8. The strategy
is to consider a pile of cylinders with a common2 rotation axis parallel to the coronal plane; such
cylinders together have to contain the lungs and leave out all the rest that has the same HU, in this
case the border effects. For other organs, different solid figures may be used for sure. This operation
takes some time since the CT must be carefully analyzed by means of DICOM readers like ImageJ [47]
2This is useful but not compulsory.
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(a) (b) (c)
Figure 4.10: 2D frames from the brain selection of mouse M16 in the sagittal xy plane: (a) growth along positive
x and y directions from the seed, (b) negative x added and (c) negative y added.
or AMIDE itself. An example using the former software is displayed in Figure 4.9; supposing that in
our reference frame the transverse section corresponds to the yz plane, one has to identify
 the coordinates of the rotation axis (y0, z0);
 the interval [x1, x2] containing each cylinder;
 the radius r =
√
(y − y0)2 + (z − z0)2.
When one knows these values (in terms of either voxels or mm), Geant4 can be told to assign the lung
tissue to voxels presenting HU ∈ [4000, 6000] and included in one of the defined cylinders. The border
effects get drastically reduced and the lungs can be successfully cut when computing the dose rate,
too.
A completely different situation occurs when analyzing the brain. In our simulations it is assimilated
to the generic soft tissue, so no further actions have to be done during that step, but the following
technique could be helpful if one considered brain as a stand-alone tissue. The computational problem
we want to solve is the dose rate calculation in our ROI from the total map, therefore we need to access
to the single brain voxels, without leaving the organ, and sum their values. To do so, the following
method was developed.
1. A starting brain voxel, which can be called seed, is selected.
2. Using a composition of while cycles, the selection moves along the three directions (both positive
and negative side) until it reaches the HU discontinuity.
3. If the container tissue presents some holes, a geometric limit must be set to prevent the selection
from leaving the ROI.
As an example of instruction 3., the discontinuity between brain and cerebellum is not appreciable
with our CT, so a manual border along the x axis must be set. It is clear that the choice of the seed
is not fully arbitrary, since if the selection along a direction meets a border too early, a part of the
organ might not be reached at all. Figure 4.10 shows a sequence of the brain voxels selection of mouse
M16, in the sagittal xy plane. A straight border is visible in the lower part: as anticipated, in absence
of skull on that side, the discontinuity between brain and cerebellum had to be drawn manually.
Finally, dealing with the cost of computational time of the two methods introduced, no significant
worsening is registered when calculating the dose rate in lungs, while a small increase happens with
brain, anyway remaining in the acceptable order of magnitude of a few seconds with our devices.
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Figure 4.11: Dose rate map of BIOEMTECH mice computed by Direct Monte Carlo with 111In in the air-soft-
bone-lung approximation after 2 h from a 7.40 MBq injection; the coronal plane shows the upper mouse.
4.4.2 Absorbed dose calculation
We are now ready to proceed with the Direct Monte Carlo simulations and compute the dose rate,
applying the organ selection for lungs and brain as explained in the previous paragraph to the whole
series of murine CTs. As the activity in each image was expressed in arbitrary units, a TIA of 7.40
MBq was considered for each mouse as reported in Verona et al., 2021; letting it decay exponentially
for 2 h with the proper λ of 111In (t1/2 = 2.8047 d), 7.25 MBq were obtained and the same number
of events was simulated to get the dose per second, in the rough assumption that the mice did not
urinate during the first 120 min.3 Alternatively, an arbitrarily high number of events can also be run
and later normalized. A calibration factor was obtained for each mouse dividing 7.25 MBq by its
total activity expressed by the SPECT counts at 2 h. Letting 111In decay until 4 and 8 h, one obtains
respectively 7.10 MBq and 6.81 MBq, but applying the calibration factors to the new SPECT counts
it turned out that
 at 4 h both mice had about 6.27 MBq, so 0.83 MBq could be considered expelled by urination;
 at 8 h MX had 4.14 MBq and M16 had 3.64 MBq, meaning different multiple expulsions.
The dose rate maps for the whole time distribution are illustrated in Figures 4.11, 4.12 and 4.13, and
some considerations may be made. A higher dose rate is reached in lungs without appreciable border
effects, as visible mostly — but not only — in the transverse sections, meaning that our strategy to
set the MOBY definition of lung tissue and isolate such organs during the HU assignment is working.
Anyway, some thickened border lines are visible also far from the rib cage, probably due to the noise
that implied the presence of decay events occurring in air and arriving to the mouse’s external surface.
This observation is corroborated by the deposition of a certain amount of dose on the instrumentation;
moreover, a suspicious noisy pattern appears near the belly of the lower mouse, M16.
Now, Geant4 allows the user to switch the selected radionuclide and associate a different one to the
111In-IP-001 biodistribution. Since ISOLPHARM is mainly interested in the behavior of 111Ag and it
3Such data were unfortunately missing.
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Dose rate map with direct Monte Carlo



































Figure 4.12: Dose rate map of BIOEMTECH mice computed by Direct Monte Carlo with 111In in the air-soft-
bone-lung approximation after 4 h from a 7.40 MBq injection; the coronal plane shows the upper mouse.
















Dose rate map with direct Monte Carlo




































Figure 4.13: Dose rate map of BIOEMTECH mice computed by Direct Monte Carlo with 111In in the air-soft-
bone-lung approximation after 8 h from a 7.40 MBq injection; the coronal plane shows the upper mouse.
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Figure 4.14: Dose rate map of BIOEMTECH mice computed by Direct Monte Carlo with 111Ag in the air-soft-
bone-lung approximation with 7.25 MBq 2 h after the injection; the coronal plane shows the upper mouse.
is not unlikely that such a drug could be radiolabelled with the silver isobar as well, bringing a similar
distribution, we can change and insert it. Naturally, we expect a pretty higher short range dose due
to the β− emission; the same activity may be kept at the injection (or in a single frame), recalling
that now the population has changed its decay rate, but a configuration with the same number of
nuclides — i.e. the same quantity of radiopharmaceutical — is also reproducible by adding a factor
which represents the ratio between the two half-lives. Remember that t1/2 = 7.45 d for
111Ag, so
identifying the number of nuclides (activity) would imply a lower activity (higher number of nuclides).
For instance, Figure 4.14 shows the result of such a substitution maintaining an activity of 7.25 MBq
after 2 h from the injection.
Of course such a modality of visualization is a little disturbed by the troublesome presence of the highly
radioactive urinary bladders, mainly in the pictures at 2 h. However, with the help of the instruments
developed for the organ selection, we are now able to distinguish separately either lungs or brain and
check the time evolution of their dose rate. Due to the lack of points close to the injection time,
only an approximate interpolation exploiting the condition b  c, hence neglecting the subtracted
exponential in Eq. 4.26 (see also again Figure 4.4), could be carried out, using the function
Ḋ(t) ≈ a e−bt (4.29)
whose integral over [0, T ] yields the absorbed dose









The plots for 111In in lungs and brain of both mice are shown in Figure 4.15, whereas Table 4.3
illustrates the fit parameters a and b, the dose integral D∞ and λbio = b − λrad. Dose rates appear
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Dose rate in brain
MX
M16
Figure 4.15: Dose rate of mice MX and M16 in (a) lungs and (b) brain at 2, 4 and 8 h after the 111In injection
with exponential fit.
Organ a [µGy/s] b [s−1] D∞ [mGy] λbio [s
−1]
Lungs MX 10.34 4.90 · 10−5 211 4.61 · 10−5
Lungs M16 11.93 5.05 · 10−5 236 4.76 · 10−5
Brain MX 1.69 6.90 · 10−5 25 6.61 · 10−5
Brain M16 2.49 6.27 · 10−5 40 5.98 · 10−5
Table 4.3: Exponential fit parameters, absorbed dose integral and λbio for BIOEMTECH mice in lungs and
brain with 111In-IP-001.















where voxel volume v and organ density ρ are constant and n ≡ V/v is the number of voxels composing
the organ. Recall anyway that these values represent a demonstrative toy-model and should not be
taken as likely estimates, because of:
 the coarse assumption of no urination within the first 120 min we were forced to adopt;
 the fact that repeated CTs required different masks for the same organ;
 the radiation produced by noise from outside the mice;
 the fact that we neglected the c exponential since our SPECTs were taken long after the injection,
so that we did not consider at all the organ uptake phase.
Regarding the difference between the two mice, brain has a worse agreement than lungs, meaning
that its cutting algorithm can still be improved. More reliable results would be obtained by using a
longer and closer to injection SPECT or PET series with anesthetized mice, as done for instance by
Gupta et al., 2019: in this way, the urination issue could be controlled and a single CT could be used.
However, our absorbed dose values seem to belong to the same order of magnitude as the ones found
in the cited reference study, where hundreds of mGy were obtained simulating a 15.22 MBq injection
of 18F — more energetic and radioactive than 111In — in a murine population.
Having this data, we could further exploit our toy-model to show how one can estimate the dose
released by another radiolabelling of the same pharmaceutical. Let us call λAg the disintegration
constant of 111Ag and suppose to have 7.25 MBq of it at time t = 2 h, like in Figure 4.14. The new
exponential parameters would become
b′ = λAg + λbio (4.33)
c′ = λAg + λ̄bio (4.34)
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Organ Ḋ(2 h) [µGy/s] b′ [s−1] a′ [µGy/s] D∞ [mGy]
Lungs MX 39.70 5.01 · 10−5 56.94 1137
Lungs M16 46.19 5.16 · 10−5 66.97 1298
Brain MX 5.15 7.01 · 10−5 8.53 122
Brain M16 7.98 6.38 · 10−5 12.63 198
Table 4.4: Exponential parameters and absorbed dose integral for BIOEMTECH mice in lungs and brain with
a hypothetical radiopharmaceutical labelled with 111Ag following the biodistribution of 111In-IP-001, calibrated
on 7.25 MBq at 2 h.
although, obviously, c′ will be missing; a′ could instead be extracted, applying the ROI cuts to the





The results for the silver isobar are summarized in Table 4.4; as expected, Ḋ∞ shows higher values
due to the β− emission of 111Ag. Remember that, though we previously chose to calibrate the new
radionuclide with 7.25 MBq after 2 h from the injection, one could also fix a particular value of TIA:




The main purpose of this master thesis was to develop different methods of computed dosimetry for
nuclear medicine in the context of the ISOLPHARM project (INFN-LNL), by means of instruments
including Monte Carlo codes (mainly Geant4) and PET/CT or SPECT/CT imaging. After an intro-
ductory part that provided some basic information about the underlying concepts of medical physics
and ISOLPHARM in general, Chapter 3 followed the dosimetric procedure developed by the MIRD.
This technique is based on a convolution between a 3D function expressing the activity distribution
in the patient — namely a PET or a SPECT — and a 3D kernel whose coefficients reflect the ef-
fectiveness of a radiation source in a tissue. Such a kernel could be built simulating multiple decay
events on Geant4 in virtual volumes of several tissues, subdivided in either concentric shells (DPK
coefficients) or voxels (VSV). A database containing DPKs and VSVs of the main radionuclides of
medical interest for ISOLPHARM was produced and, when possible, compared with literature. Fur-
thermore, the energy deposition of the sources was evaluated: in particular, it turned out that 111Ag,
the most promising and innovative radioisotope of the project, behaves similarly to the theranostic
nuclide 177Lu, thus a future use in nuclear medicine of this silver isotope can be hypothesized.
Once the database was completed, some examples of convolution were given using a PET/CT hy-
brid pre-clinical imaging carried out at INFN-LNS with 18F-FDG. The related VSVs were utilized to
compute the dose rate map in a murine phantom
 in the 100% soft tissue approximation;
 in the three tissues approximation, involving compact bone, lung and soft tissue, which was
possible thanks to the morphological information contained by the CT.
Moreover, the former map was compared to an equivalent one drawn using DPKs; the resulting dose
rate distribution was less peaked on the sources, probably because, contrary to the small DPK core,
the size of the source voxel was comparable to the mean range in water of the e+ emitted by 18F. It is
important to underline that the construction of the dataset was computationally time-expensive, but
then the convolutions took a negligible time.
Subsequently, Chapter 4 began with the exposition of another computed dosimetry method, which
was named Direct Monte Carlo: indeed, it consists in a complete simulation of the decay events
suggested by an emission tomography in the Geant4 virtual reproduction of a CT, where the dose
rate is counted in every voxel. This strategy was tried on the same LNS mouse and a comparison
with the MIRD schema results was made. Direct Monte Carlo is more time-expensive but it is also
expected to be more precise: in this assumption we noticed that, when using more than one tissue,
some discrepancies occur near the borders. Our explanation was that the MIRD schema neglected
the dose rate contributions at long range and, mostly, the cross-absorbed dose passing through the
discontinuities between tissues.
In the second half of Chapter 4, a theoretical model for the biodistribution of the activity in regions of
interest was introduced and later applied to a dynamic SPECT/CT pre-clinical imaging. The math-
ematical formalization of the problem showed that the activity decrease in an organ is modulated by
the the radioactive disintegration constant, λrad, together with a biological decay constant, λbio. The
sum of such constants is related to the eigenvalues of the Markov transition matrix of the body-organ
system, including radioactive decay and physiological elimination of the radiopharmaceutical. The dy-
namical imaging was provided by the BIOEMTECH group and allowed us to study three subsequent
SPECT/CTs of two mice after an injection of 111In-IP-001. Exploiting the higher resolution of those
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CTs, two methods to select specific organs from a 3D map were developed. Using all these tools, it
was possible to calculate the absorbed dose by integration over a period; the reconstructed dose rate
curves were approximated due to the long time distance from the injection of our SPECTs, however
the results for 111In appeared compatible with the reference literature. Finally, since it is thought that
future radiopharmaceuticals labelled with 111Ag may follow the same biodistribution, the method was
extended to predict a hypothetical pre-clinical experiment with this nuclide.
We can conclude by pointing out some possible future steps of this research in the ISOLPHARM
project. First, Direct Monte Carlo appeared to have an appropriate CPU timing for pre-clinical stud-
ies, but it could be interesting to exploit the MIRD schema toghether with the former to investigate
the contribution of cross-absorbed dose in addition to self-absorbed dose. Moreover, further simu-
lations based on dynamic imaging taken at short times after the injection would allow to improve
the theoretical characterization of the biodistribution and to have more reliable predictions for future
pre-clinical experiments. Finally, trying to automatize the selection process of all the murine and
human organs from a CT could be an engaging challenge.
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Appendix A
Radioactive source DPK This appendix shows Geant4 DPK curves in water for radioactive
sources not present in our literature of reference: 18F (100% pure β+-emitter), 64Cu (β+, β− and
γ) and 89Sr (pure β−).
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Convolution of subsequent decays The current paragraph will formalize a simple model for
the convolution of sources decaying twice with different half-lives, following the MIRD schema; the
example of technetium will be used, but the conclusion will be absolutely general. In radioactivity
and nuclear physics, a couple of mother and daughter nuclei like 99mTc and 99Tc g.s. can be classified
in the non-equilibrium condition since tm1/2 < t
g
1/2; solving Bateman’s differential equations for the
number N of metastable and g.s. nuclei [15] [16]{
Ṅm(t) = −λmNm(t)
Ṅg(t) = λmNm(t)− λgNg(t)
we obtain {






where λ and N0 indicate the radioactive disintegration constants and the initial quantities of nuclides.
The resulting trend is illustrated in Figure B.1(a), where the g.s. curve seems like it is not decaying
because of its very long half-life. Recall that, as we said in Section 1.1, the activity of a population of
radionuclides A(t) is trivially connected to N(t) by Eq. 1.4. Now, let us suppose to have two different
VSV kernels Sm and Sg for the two nuclides, like in Figure B.1(b); in fact, with Geant4 it is possible
to compute
 Sm by placing
99mTc as radioactive source and killing all the 99Tc g.s. ions as soon as they are
produced;
 Sg by using directly
99Tc as source.
Regarding the activity, which could be realistically taken from a SPECT, it would be referred to 99mTc,
namely Am(t) = λmNm(t). In order to calculate Ag(t), it is fundamental to know the initial ratio
N0g/N0m at the production of the radiopharmaceutical or at the injection moment. If this happens,
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Voxelized dosimetry (3 mm), Tc-99m and TC-99 g.s. in soft tissue
Geant4, m
Geant4, g.s.
Geant4 (Amato, 2013), m
Figure B.1: (a) Decay curves of a 99mTc and 99Tc population assuming N0g = 0. (b) VSV curves of
99mTc,
compared with Amato et al., 2013, and 99Tc in soft tissue using Geant4.
67
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one can find N0m from Bateman’s equations (if it is not known itself) using an appropriate value for





Am(rs, t)Sm(rt ← rs) +Ag(rs, t)Sg(rt ← rs)
Having a series of subsequent SPECT each activity could obviously be integrated, yielding the absorbed
dose in a time window. These considerations can be extended to a generic medical radioisotope whose
daughter nucleus decays again once or even more times.
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